

## Appendix H. Aim 3 Single Augmenting Class Analyses

## **Appendix H: Aim 3 Single Augmenting Class Analyses**

**For all subsequent model tables:**

**Model 0: Unadjusted**

**Model 1: Adjusted for sociodemographics, comorbidities, prescribing facility factors, service utilization factors**

**Model 2: Propensity weighted**

## Changes in PTSD Checklist Score by Augmenting Medication Group - Male vs. Female

### Male

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	61.1679	60.3265	-0.84139	(-0.842,-0.826)	0.0024	-1.38%
Mirtazapine	60.0949	58.8347	-1.26014	(-1.261,-1.245)	<.0001	-2.10%
Prazosin	61.7926	60.2784	-1.5142	(-1.515,-1.499)	<.0001	-2.45%
Tricyclics	59.7494	58.55	-1.1994	(-1.2,-1.184)	0.0165	-2.01%

### Number of Windows - Male

Medications	n(pre)	n(post)
Antipsychotics	2989	3188
Mirtazapine	2865	2670
Prazosin	10103	9237
Tricyclics	859	756

### Female

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	61.7141	60.0459	-1.66827	(-1.669,-1.653)	0.0477	-2.70%	0.3512
Mirtazapine	60.9612	59.1005	-1.8607	(-1.862,-1.846)	0.0265	-3.05%	0.4974
Prazosin	62.4596	60.2519	-2.20773	(-2.209,-2.193)	<.0001	-3.54%	0.1338
Tricyclics	60.279	59.7053	-0.5737	(-0.575,-0.559)	0.5438	-0.95%	0.5583

### Number of Windows - Female

Medications	n(pre)	n(post)
Antipsychotics	311	351
Mirtazapine	325	306
Prazosin	1078	1038
Tricyclics	226	229

**Changes in PTSD Checklist Score by Augmenting Medication Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: male	-0.41014	(-1.173,0.353)	-0.40787	(-1.169,0.354)	-0.39125	(-1.054,0.271)
Mirtazapine: female	-0.18	(-2.465,2.105)	-0.14607	(-2.426,2.134)	0.12956	(-1.818,2.077)
p-value for 3-way interaction	0.85145		0.83094		0.61979	
Prazosin: male	-0.69156	(-1.291,-0.092)	-0.70316	(-1.301,-0.105)	-0.72919	(-1.35,-0.108)
Prazosin: female	-0.56535	(-2.383,1.253)	-0.6503	(-2.465,1.164)	-0.19813	(-1.985,1.589)
p-value for 3-way interaction	0.89719		0.95675		0.58212	
Tricyclics: male	-0.3002	(-1.466,0.865)	-0.36525	(-1.528,0.798)	-0.54188	(-1.245,0.162)
Tricyclics: female	1.37792	(-1.155,3.911)	1.16021	(-1.367,3.687)	1.15332	(-0.86,3.166)
p-value for 3-way interaction	0.23821		0.28246		0.11922	
overall 3-way interaction p-value	0.62893		0.67588		0.44744	

**Changes in PTSD Checklist Score by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	61.0677	58.0406	-3.02709	(-3.028,-3.012)	0.0054	-4.96%
Mirtazapine	59.2128	57.5945	-1.61827	(-1.619,-1.603)	0.0381	-2.73%
Prazosin	61.8069	59.9116	-1.89534	(-1.896,-1.88)	<.0001	-3.07%
Tricyclics	56.8957	57.0914	0.19569	(0.195,0.211)	0.9115	0.34%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	286	195
Mirtazapine	455	348
Prazosin	1215	886
Tricyclics	91	70

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	61.2444	60.428	-0.81642	(-0.817,-0.801)	0.0026	-1.33%	0.0488
Mirtazapine	60.3465	59.0408	-1.30563	(-1.307,-1.291)	<.0001	-2.16%	0.7069
Prazosin	61.8658	60.3091	-1.5567	(-1.558,-1.542)	<.0001	-2.52%	0.498
Tricyclics	60.1378	58.9827	-1.15503	(-1.156,-1.14)	0.0114	-1.92%	0.4576

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	3014	3344
Mirtazapine	2735	2628
Prazosin	9966	9389
Tricyclics	994	915

Changes in PTSD Checklist Score by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: >=65	1.43039	(-1.128,3.989)	1.28642	(-1.263,3.835)	1.39478	(-0.834,3.624)
Mirtazapine: <65	-0.48493	(-1.245,0.275)	-0.45867	(-1.217,0.3)	-0.46185	(-1.116,0.193)
p-value for 3-way interaction	0.1596		0.19841		0.11728	
Prazosin: >=65	1.09746	(-1.171,3.366)	0.95641	(-1.303,3.216)	1.09736	(-1.035,3.23)
Prazosin: <65	-0.76032	(-1.35,-0.171)	-0.75948	(-1.348,-0.171)	-0.81061	(-1.421,-0.2)
p-value for 3-way interaction	0.12029		0.14974		0.09177	
Tricyclics: >=65	3.35927	(-0.769,7.487)	3.2087	(-0.901,7.318)	3.62717	(1.197,6.057)
Tricyclics: <65	-0.24123	(-1.323,0.841)	-0.33761	(-1.417,0.742)	-0.67751	(-1.368,0.013)
p-value for 3-way interaction	0.09818		0.10186		0.00084	
overall 3-way interaction p-value	0.30321		0.34085		0.01025	

**Changes in PTSD Checklist Score by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	60.9212	60.1519	-0.76932	(-0.77,-0.754)	0.0255	-1.26%
Mirtazapine	59.5126	58.074	-1.43862	(-1.44,-1.424)	0.0002	-2.42%
Prazosin	60.8224	59.5388	-1.28361	(-1.285,-1.269)	<.0001	-2.11%
Tricyclics	59.6236	58.31	-1.31361	(-1.315,-1.299)	0.032	-2.20%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	1655	1956
Mirtazapine	1344	1396
Prazosin	5858	5930
Tricyclics	507	454

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	61.52	60.4208	-1.0992	(-1.1,-1.084)	0.0073	-1.79%	0.5374
Mirtazapine	60.6229	59.4945	-1.12839	(-1.129,-1.113)	0.003	-1.86%	0.5647
Prazosin	62.9582	61.0988	-1.85939	(-1.86,-1.844)	<.0001	-2.95%	0.0413
Tricyclics	60.0195	59.2486	-0.77092	(-0.772,-0.756)	0.2269	-1.28%	0.5391

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	1645	1583
Mirtazapine	1846	1580
Prazosin	5323	4345
Tricyclics	578	531

Changes in PTSD Checklist Score by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: OEF/OIF	-0.67156	(-1.664,0.321)	-0.67817	(-1.669,0.313)	-0.72992	(-1.555,0.096)
Mirtazapine: other era	-0.0124	(-1.081,1.056)	0.02172	(-1.043,1.086)	0.27763	(-0.689,1.244)
p-value for 3-way interaction	0.37557		0.34552		0.12032	
Prazosin: OEF/OIF	-0.53563	(-1.279,0.208)	-0.54589	(-1.288,0.197)	-0.6489	(-1.419,0.121)
Prazosin: other era	-0.78974	(-1.676,0.096)	-0.83134	(-1.714,0.051)	-0.5897	(-1.495,0.316)
p-value for 3-way interaction	0.66672		0.62761		0.92224	
Tricyclics: OEF/OIF	-0.51183	(-1.958,0.934)	-0.58728	(-2.031,0.856)	-0.66183	(-1.544,0.22)
Tricyclics: other era	0.49785	(-1.022,2.018)	0.37677	(-1.138,1.891)	0.05334	(-0.957,1.064)
p-value for 3-way interaction	0.34551		0.36639		0.29596	
overall 3-way interaction p-value	0.32475		0.28482		0.26773	



**Changes in Primary Care PTSD Score by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	2.6977	2.6099	-0.08779	(-0.14,-0.03)	0.0012	-3.25%
Mirtazapine	2.4634	2.3587	-0.10472	(-0.17,-0.04)	0.0017	-4.25%
Prazosin	2.9733	2.92	-0.05328	(-0.09,-0.01)	0.0092	-1.79%
Tricyclics	2.4016	2.1821	-0.21956	(-0.32,-0.12)	<.0001	-9.14%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	9722	5425
Mirtazapine	7043	3627
Prazosin	16435	6526
Tricyclics	2651	1629

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	2.4106	2.4426	0.031991	(0.02,0.05)	0.0002	1.33%	<.0001
Mirtazapine	2.0515	2.0705	0.019013	(0.01,0.03)	<.0001	0.93%	<.0001
Prazosin	2.8656	2.9068	0.041204	(-0.03,0.11)	0.2331	1.44%	0.0709
Tricyclics	2.1095	2.153	0.04352	(0.01,0.07)	0.0041	2.06%	0.0048

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	1000	579
Mirtazapine	803	469
Prazosin	1757	658
Tricyclics	706	434

**Changes in Primary Care PTSD Score by Augmenting Medication Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: male	-0.01693	(-0.07,0.03)	-0.00426	(-0.04,0.03)	-0.01279	(-0.06,0.04)
Mirtazapine: female	-0.01298	(-0.33,0.3)	-0.00357	(-11.54,11.53)	-0.02359	(-0.24,0.19)
<b>p-value for 3-way interaction</b>	0.90155		0.93546		0.96244	
Prazosin: male	0.03451	(-0.02,0.09)	0.0429	(-0.02,0.1)	0.03563	(-0.03,0.11)
Prazosin: female	0.00921	(-0.66,0.67)	0.00893	(-0.4,0.42)	0.029	(-0.26,0.32)
<b>p-value for 3-way interaction</b>	0.74175		0.70967		0.89583	
Tricyclics: male	-0.13177	(-0.22,-0.04)	-0.12889	(-0.22,-0.04)	-0.24528	(-0.32,-0.17)
Tricyclics: female	0.01153	(-0.15,0.17)	0.00705	(-0.14,0.15)	0.02066	(-0.17,0.21)
<b>p-value for 3-way interaction</b>	0.20113		0.23519		0.01677	
<b>overall 3-way interaction p-value</b>	0.43383		0.47298		0.0349	

## Changes in Primary Care PTSD Score by Augmenting Medication: Age 65 and Over vs. Under 65

### Age >=65

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	2.1526	2.0192	-0.13337	(-0.26,-0.01)	0.0378	-6.20%
Mirtazapine	2.1054	1.9769	-0.12851	(-0.27,0.01)	0.0674	-6.10%
Prazosin	2.6471	2.4874	-0.15969	(-0.25,-0.07)	0.0008	-6.03%
Tricyclics	2.0292	1.6224	-0.4068	(-0.64,-0.17)	0.0007	-20.05%

### Number of Windows - Age >=65

Medications	n(pre)	n(post)
Antipsychotics	1266	786
Mirtazapine	1297	711
Prazosin	2419	1099
Tricyclics	362	260

### Age <65

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	2.7404	2.6804	-0.06	(-0.07,-0.05)	<.0001	-2.19%	<.0001
Mirtazapine	2.4838	2.399	-0.08485	(-0.11,-0.06)	<.0001	-3.42%	<.0001
Prazosin	3.0113	2.9967	-0.0146	(-0.02,-0.01)	<.0001	-0.49%	<.0001
Tricyclics	2.3778	2.2558	-0.12199	(-0.22,-0.02)	0.0151	-5.13%	<.0001

### Number of Windows - Age <65

Medications	n(pre)	n(post)
Antipsychotics	9456	5218
Mirtazapine	6549	3385
Prazosin	15773	6085
Tricyclics	2995	1803

**Changes in Primary Care PTSD Score by Augmenting Medication: Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: >=65	0.00486	(-0.41,0.42)	0.02098	(-0.19,0.23)	0.01533	(-0.3,0.33)
Mirtazapine: <65	-0.02486	(-0.09,0.04)	-0.00862	(-0.06,0.04)	-0.02637	(-0.09,0.04)
<b>p-value for 3-way interaction</b>	0.76535		0.75743		0.71601	
Prazosin: >=65	-0.02632	(-1.11,1.06)	-0.02879	(-1.58,1.52)	-0.03108	(-0.46,0.4)
Prazosin: <65	0.04539	(-0.02,0.11)	0.05178	(-0.01,0.12)	0.05077	(-0.03,0.13)
<b>p-value for 3-way interaction</b>	0.68787		0.63223		0.5691	
Tricyclics: >=65	-0.27343	(-0.49,-0.06)	-0.2877	(-0.52,-0.05)	-0.41502	(-0.58,-0.25)
Tricyclics: <65	-0.062	(-0.15,0.02)	-0.05805	(-0.14,0.02)	-0.18123	(-0.25,-0.11)
<b>p-value for 3-way interaction</b>	0.05627		0.06183		0.00149	
<b>overall 3-way interaction p-value</b>	0.20648		0.21658		0.00273	

**Changes in Primary Care PTSD Score by Augmenting Medication: Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	3.093	2.9659	-0.12714	(-0.24,-0.02)	0.023	-4.11%
Mirtazapine	2.8419	2.7227	-0.11919	(-0.26,0.02)	0.0983	-4.19%
Prazosin	3.1611	3.1702	0.00909	(-0.06,0.07)	0.7849	0.29%
Tricyclics	2.8339	2.6991	-0.13483	(-0.34,0.07)	0.2072	-4.76%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	2935	1362
Mirtazapine	1974	849
Prazosin	7169	2546
Tricyclics	849	434

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	2.5119	2.4846	-0.02724	(-0.03,-0.02)	<.0001	-1.08%	<.0001
Mirtazapine	2.2799	2.2219	-0.05797	(-0.07,-0.05)	<.0001	-2.54%	<.0001
Prazosin	2.834	2.7808	-0.05317	(-0.06,-0.05)	<.0001	-1.88%	<.0001
Tricyclics	2.1731	2.0366	-0.13647	(-0.16,-0.11)	<.0001	-6.28%	<.0001

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	7787	4642
Mirtazapine	5872	3247
Prazosin	11023	4638
Tricyclics	2508	1629

**Changes in Primary Care PTSD Score by Augmenting Medication: Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: OEF/OIF	0.00795	(-0.51,0.53)	0.00722	(-0.51,0.53)	-0.01007	(-0.09,0.07)
Mirtazapine: other era	-0.03073	(-0.1,0.04)	-0.013	(-0.07,0.05)	-0.01582	(-0.08,0.05)
p-value for 3-way interaction	0.68118		0.84762		0.97034	
Prazosin: OEF/OIF	0.13623	(0.01,0.26)	0.11151	(-0.01,0.23)	0.13563	(-0.02,0.29)
Prazosin: other era	-0.02593	(-0.12,0.07)	-0.00896	(-0.27,0.25)	-0.01757	(-0.14,0.1)
p-value for 3-way interaction	0.04231		0.11933		0.10933	
Tricyclics: OEF/OIF	-0.00769	(-0.09,0.08)	-0.01075	(-0.11,0.09)	-0.14547	(-0.28,-0.01)
Tricyclics: other era	-0.10923	(-0.2,-0.02)	-0.10122	(-0.19,-0.01)	-0.22908	(-0.31,-0.15)
p-value for 3-way interaction	0.28825		0.34114		0.10855	
overall 3-way interaction p-value	0.19156		0.37781		0.17993	

**Changes in Mental Health Emergency Visit (per 100 patient years) by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	11.2705	8.8634	-2.4071	(-3.23,-1.58)	<.0001	-21.36%
Mirtazapine	9.1033	6.8923	-2.21099	(-3.01,-1.41)	<.0001	-24.29%
Prazosin	7.6278	5.6553	-1.97249	(-2.45,-1.49)	<.0001	-25.86%
Tricyclics	4.1814	3.5206	-0.66082	(-1.42,0.1)	0.0883	-15.80%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	29413	29413
Mirtazapine	22750	22750
Prazosin	48061	48061
Tricyclics	8777	8777

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	14.7854	11.566	-3.2194	(-27.18,20.74)	0.7923	-21.77%	<.0001
Mirtazapine	11.1266	8.4376	-2.68892	(-10.91,5.54)	0.5217	-24.17%	0.0113
Prazosin	10.7852	7.7105	-3.07474	(-50.37,44.22)	0.8986	-28.51%	<.0001
Tricyclics	5.3226	4.7849	-0.53763	(-1.74,0.67)	0.3826	-10.10%	0.0111

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	2516	2516
Mirtazapine	2157	2157
Prazosin	4228	4228
Tricyclics	1860	1860

**Changes in Mental Health Emergency Visit (per 100 patient years) by Augmenting Medication Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: male	0.19611	(-0.45,0.84)	0.02318	(-0.04,0.09)	0.37777	(-1.88,2.63)
Mirtazapine: female	0.53048	(-5.8,6.86)	-0.0237	(-0.26,0.21)	-0.01458	(-0.31,0.28)
<b>p-value for 3-way interaction</b>	0.97238		0.96686		0.78088	
Prazosin: male	0.43461	(-0.36,1.23)	0.11219	(-0.06,0.28)	0.50881	(-9.9,10.92)
Prazosin: female	0.14466	(-0.36,0.65)	-0.07368	(-0.29,0.14)	0.48464	(-1.36,2.33)
<b>p-value for 3-way interaction</b>	0.85467		0.82604		0.93172	
Tricyclics: male	1.74628	(-4.41,7.9)	0.7303	(-1.41,2.88)	1.15494	(-12.55,14.86)
Tricyclics: female	2.68176	(-6.74,12.11)	0.79772	(-1.54,3.13)	1.65778	(-24.86,28.18)
<b>p-value for 3-way interaction</b>	0.79879		0.75969		0.844	
<b>overall 3-way interaction p-value</b>	0.98503		0.97465		0.97565	



**Changes in Mental Health Emergency Visit (per 100 patient years) by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	6.8723	3.9025	-2.96973	(-4.39,-1.55)	<.0001	-43.21%
Mirtazapine	4.9292	4.0203	-0.90893	(-2.09,0.27)	0.1318	-18.44%
Prazosin	3.338	2.1458	-1.19213	(-1.86,-0.52)	0.0005	-35.71%
Tricyclics	2.0196	2.2032	0.1836	(-1.1,1.47)	0.7791	9.09%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	5253	5253
Mirtazapine	5721	5721
Prazosin	10066	10066
Tricyclics	1634	1634

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	12.4681	10.0952	-2.37292	(-3.44,-1.3)	<.0001	-19.03%	<.0001
Mirtazapine	10.5754	7.9224	-2.65298	(-3.73,-1.57)	<.0001	-25.09%	<.0001
Prazosin	8.9667	6.6978	-2.26891	(-2.8,-1.73)	<.0001	-25.30%	<.0001
Tricyclics	4.8095	4.0209	-0.78863	(-1.31,-0.26)	0.0033	-16.40%	<.0001

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	26676	26676
Mirtazapine	19186	19186
Prazosin	42223	42223
Tricyclics	9003	9003

**Changes in Mental Health Emergency Visit (per 100 patient years) by Augmenting Medication Group - Age 65 and Over vs. Under 65**

<b>Antipsychotics (Reference)</b>	<b>Difference</b>	<b>95% CI</b>	<b>Difference</b>	<b>95% CI</b>	<b>Difference</b>	<b>95% CI</b>
<b>Mirtazapine: &gt;=65</b>	2.0608	(-0.01,4.13)	2.20716	(0.34,4.08)	2.3053	(0.25,4.36)
<b>Mirtazapine: &lt;65</b>	-0.28006	(-0.73,0.17)	-0.16216	(-0.38,0.06)	-0.11326	(-0.34,0.12)
<b>p-value for 3-way interaction</b>	0.02479		0.0078		0.01692	
<b>Prazosin: &gt;=65</b>	1.7776	(-3.38,6.94)	1.82051	(-2.64,6.28)	1.947	(-2.36,6.26)
<b>Prazosin: &lt;65</b>	0.10401	(-0.03,0.24)	-0.03615	(-0.08,0)	0.17183	(-0.19,0.53)
<b>p-value for 3-way interaction</b>	0.2845		0.2046		0.26287	
<b>Tricyclics: &gt;=65</b>	3.15333	(-0.45,6.76)	3.30293	(0.11,6.49)	3.67035	(1.8,5.54)
<b>Tricyclics: &lt;65</b>	1.58429	(-9.34,12.51)	0.54903	(-2.65,3.74)	0.64156	(-0.31,1.59)
<b>p-value for 3-way interaction</b>	0.11828		0.06411		0.00005	
<b>overall 3-way interaction p-value</b>	0.10206		0.0333		0.00052	

**Changes in Mental Health Emergency Visit (per 100 patient years) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	16.1301	12.1233	-4.00685	(-6.2,-1.82)	0.0003	-24.84%
Mirtazapine	11.5617	7.6574	-3.90428	(-6.01,-1.8)	0.0003	-33.77%
Prazosin	10.4701	8.2637	-2.20639	(-3.24,-1.17)	<.0001	-21.07%
Tricyclics	4.1399	3.5569	-0.58309	(-2.29,1.13)	0.5038	-14.08%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	5840	5840
Mirtazapine	3970	3970
Prazosin	14594	14594
Tricyclics	1715	1715

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	10.5217	8.3943	-2.12733	(-2.53,-1.73)	<.0001	-20.22%	<.0001
Mirtazapine	8.8456	6.9064	-1.93915	(-2.54,-1.33)	<.0001	-21.92%	0.0031
Prazosin	6.8815	4.876	-2.00557	(-2.27,-1.74)	<.0001	-29.14%	<.0001
Tricyclics	4.4273	3.7772	-0.65008	(-3.01,1.71)	0.5893	-14.68%	0.6062

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	26089	26089
Mirtazapine	20937	20937
Prazosin	37695	37695
Tricyclics	8922	8922

**Changes in Mental Health Emergency Visit (per 100 patient years) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: OEF/OIF	0.10257	(-0.11,0.32)	-0.14352	(-0.39,0.11)	-0.01692	(-0.05,0.02)
Mirtazapine: other era	0.18818	(-0.98,1.35)	0.04913	(-0.2,0.3)	0.44621	(-2.93,3.82)
<b>p-value for 3-way interaction</b>	0.4857		0.40285		0.35285	
<b>Prazosin: OEF/OIF</b>	1.80046	(-5.03,8.63)	0.41649	(-0.9,1.73)	1.48651	(-4.06,7.04)
Prazosin: other era	0.12176	(0,0.25)	-0.08346	(-0.16,-0.01)	0.27897	(-0.28,0.84)
<b>p-value for 3-way interaction</b>	0.14052		0.07698		0.32855	
<b>Tricyclics: OEF/OIF</b>	3.42376	(-10.28,17.13)	0.95046	(-2.22,4.12)	2.26664	(-12.87,17.41)
Tricyclics: other era	1.47725	(-3.69,6.64)	0.6839	(-1.31,2.68)	0.93775	(-)
<b>p-value for 3-way interaction</b>	0.82306		0.78846		0.79225	
<b>overall 3-way interaction p-value</b>	0.22227		0.09698		0.33882	

**Changes in Mental Health Hospitalization (per 100 patient years) by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	14.6602	10.6008	-4.05943	(-4.86,-3.26)	<.0001	-27.69%
Mirtazapine	10.8352	7.7231	-3.11209	(-3.91,-2.31)	<.0001	-28.72%
Prazosin	9.7147	6.6707	-3.04405	(-3.53,-2.56)	<.0001	-31.33%
Tricyclics	4.6257	3.3269	-1.29885	(-2.03,-0.57)	0.0005	-28.08%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	29413	29413
Mirtazapine	22750	22750
Prazosin	48061	48061
Tricyclics	8777	8777

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	16.1367	11.8045	-4.33227	(-7.6,-1.06)	0.0094	-26.85%	0.0671
Mirtazapine	10.8948	7.8813	-3.01344	(-5.1,-0.92)	0.0047	-27.66%	0.8635
Prazosin	11.14	7.8761	-3.26395	(-5.57,-0.96)	0.0055	-29.30%	0.0025
Tricyclics	4.086	3.3871	-0.69892	(-1.43,0.04)	0.0621	-17.11%	0.6452

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	2516	2516
Mirtazapine	2157	2157
Prazosin	4228	4228
Tricyclics	1860	1860

Changes in Mental Health Hospitalization (per 100 patient years) by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: male	0.94734	(-5.91,7.81)	0.33399	(-1.7,2.37)	0.89861	(-18.11,19.9)
Mirtazapine: female	1.31883	(-38.44,41.07)	0.20421	(-4.98,5.39)	0.79959	(-28.99,30.59)
p-value for 3-way interaction	0.98576		0.9831		0.9169	
Prazosin: male	1.01538	(-0.7,2.73)	0.2823	(-0.12,0.68)	0.8266	(-94.87,96.52)
Prazosin: female	1.06832	(-7.67,9.8)	0.2452	(-1.44,1.93)	0.92599	(-1.87,3.72)
p-value for 3-way interaction	0.90594		0.88845		0.82575	
Tricyclics: male	2.76058	(-)	0.96846	(-31.39,33.33)	1.09335	(-9.59,11.78)
Tricyclics: female	3.63335	(-10.82,18.09)	1.08861	(-2.56,4.74)	1.85926	(0.53,3.18)
p-value for 3-way interaction	0.6368		0.57511		0.51365	
overall 3-way interaction p-value	0.97211		0.95464		0.90224	

**Changes in Mental Health Hospitalization (per 100 patient years) by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	7.3672	4.4356	-2.93166	(-4.22,-1.64)	<.0001	-39.79%
Mirtazapine	5.2264	3.6532	-1.57315	(-2.66,-0.48)	0.0047	-30.10%
Prazosin	4.0334	2.5233	-1.51003	(-2.18,-0.84)	<.0001	-37.44%
Tricyclics	1.9584	1.836	-0.1224	(-1.28,1.04)	0.8358	-6.25%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	5253	5253
Mirtazapine	5721	5721
Prazosin	10066	10066
Tricyclics	1634	1634

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	16.2356	11.9283	-4.30724	(-5.6,-3.01)	<.0001	-26.53%	<.0001
Mirtazapine	12.5143	8.9544	-3.55989	(-4.7,-2.42)	<.0001	-28.45%	<.0001
Prazosin	11.2119	7.7801	-3.43178	(-4.14,-2.72)	<.0001	-30.61%	<.0001
Tricyclics	4.9983	3.6099	-1.38843	(-2.4,-0.38)	0.0071	-27.78%	<.0001

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	26676	26676
Mirtazapine	19186	19186
Prazosin	42223	42223
Tricyclics	9003	9003

**Changes in Mental Health Hospitalization (per 100 patient years) by Augmenting Medication Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: >=65	1.35851	(-1.58,4.3)	1.21871	(-1.03,3.46)	1.78433	(-0.88,4.44)
Mirtazapine: <65	0.74736	(-2.18,3.68)	0.24786	(-0.58,1.07)	0.6816	(-2.59,3.95)
<b>p-value for 3-way interaction</b>	0.31033		0.23305		0.16851	
Prazosin: >=65	1.42162	(-9.84,12.69)	1.17608	(-6.75,9.1)	1.61387	(-6.7,9.93)
Prazosin: <65	0.87546	(-0.44,2.19)	0.19725	(-0.06,0.45)	0.65275	(-0.88,2.19)
<b>p-value for 3-way interaction</b>	0.55365		0.48628		0.5508	
Tricyclics: >=65	2.80926	(-1.67,7.28)	2.35869	(-0.84,5.55)	2.69939	(0.08,5.32)
Tricyclics: <65	2.91882	(-31.45,37.29)	0.91647	(-8.26,10.1)	0.82377	(0.36,1.29)
<b>p-value for 3-way interaction</b>	0.21915		0.14862		0.0032	
<b>overall 3-way interaction p-value</b>	0.54911		0.404		0.0281	



**Changes in Mental Health Hospitalization (per 100 patient years) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	18.6301	14.3322	-4.29795	(-6.35,-2.25)	<.0001	-23.07%
Mirtazapine	12.0907	7.2292	-4.86146	(-6.83,-2.9)	<.0001	-40.21%
Prazosin	11.676	9.0448	-2.63122	(-3.62,-1.64)	<.0001	-22.54%
Tricyclics	3.8484	2.7405	-1.10787	(-2.61,0.39)	0.1482	-28.79%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	5840	5840
Mirtazapine	3970	3970
Prazosin	14594	14594
Tricyclics	1715	1715

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	13.9139	9.8816	-4.03235	(-4.66,-3.41)	<.0001	-28.98%	<.0001
Mirtazapine	10.6032	7.833	-2.77022	(-3.69,-1.85)	<.0001	-26.13%	0.659
Prazosin	9.1153	5.8867	-3.22854	(-3.63,-2.83)	<.0001	-35.42%	<.0001
Tricyclics	4.6626	3.4521	-1.21049	(-4.85,2.43)	0.515	-25.96%	0.0939

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	26089	26089
Mirtazapine	20937	20937
Prazosin	37695	37695
Tricyclics	8922	8922

**Changes in Mental Health Hospitalization (per 100 patient years) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: OEF/OIF	-0.56352	(-1.09,-0.04)	-0.40999	(-0.73,-0.09)	-1.29673	(-2.26,-0.33)
Mirtazapine: other era	1.26214	(-2.28,4.8)	0.52491	(-0.72,1.76)	1.4445	(-0.51,3.4)
<b>p-value for 3-way interaction</b>	0.02694		0.00862		0.00269	
Prazosin: OEF/OIF	1.66673	(-36.01,39.34)	0.35786	(-6.46,7.17)	0.77512	(-7.82,9.37)
Prazosin: other era	0.80381	(-0.04,1.65)	0.16357	(0.02,0.31)	0.82193	(-1.22,2.86)
<b>p-value for 3-way interaction</b>	0.28176		0.2013		0.78707	
Tricyclics: OEF/OIF	3.19007	(-18.4,24.78)	0.79566	(-3.74,5.33)	0.69341	(0.19,1.19)
Tricyclics: other era	2.82186	(-11.52,17.16)	1.10473	(-3.62,5.83)	1.2786	(-0.33,2.88)
<b>p-value for 3-way interaction</b>	0.67946		0.62374		0.07043	
<b>overall 3-way interaction p-value</b>	0.0201		0.00312		0.00331	

**Changes in Suicidal Thought (% endorsing) by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	20.6832	16.1024	-4.58082	(-5.9,-3.26)	<.0001	-22.15%
Mirtazapine	16.872	13.5962	-3.27579	(-4.58,-1.97)	<.0001	-19.42%
Prazosin	17.8811	15.0215	-2.85964	(-3.74,-1.98)	<.0001	-15.99%
Tricyclics	15.1653	13.9546	-1.21068	(-3.42,1)	0.2829	-7.98%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	6309	5531
Mirtazapine	5792	4572
Prazosin	14680	10357
Tricyclics	1855	1683

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	20.7754	17.1214	-3.65404	(-7.04,-0.27)	0.0346	-17.59%	0.5826
Mirtazapine	16.4537	14.8626	-1.59111	(-4.24,1.05)	0.2385	-9.67%	0.6543
Prazosin	18.4	14.4398	-3.96011	(-6.61,-1.31)	0.0034	-21.52%	0.9059
Tricyclics	11.9603	10.473	-1.48726	(-2.64,-0.34)	0.0113	-12.44%	0.007

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	624	563
Mirtazapine	583	456
Prazosin	1473	1004
Tricyclics	489	394

Changes in Suicidal Thought (% endorsing) by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: male	1.30503	(-2.08,4.69)	1.18728	(-1.9,4.27)	1.27094	(-1.71,4.25)
Mirtazapine: female	2.06293	(-5.26,9.39)	1.87802	(-4.65,8.41)	1.63593	(-5.04,8.31)
p-value for 3-way interaction	0.76885		0.76023		0.84787	
Prazosin: male	1.72118	(-0.19,3.64)	1.49646	(-0.28,3.27)	1.50687	(-0.59,3.61)
Prazosin: female	-0.30608	(-2.35,1.74)	-0.14077	(-1.31,1.03)	-0.26164	(-2.79,2.27)
p-value for 3-way interaction	0.41595		0.46883		0.52295	
Tricyclics: male	3.37014	(0.21,6.53)	3.14924	(0.29,6.01)	3.04821	(0.97,5.12)
Tricyclics: female	2.16677	(-9.55,13.89)	2.20319	(-6.5,10.9)	0.91045	(-45.3,47.12)
p-value for 3-way interaction	0.65055		0.72284		0.36189	
overall 3-way interaction p-value	0.69685		0.75243		0.6712	

**Changes in Suicidal Thought (% endorsing) by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	17.7311	13.024	-4.7071	(-7.78,-1.63)	0.0027	-26.55%
Mirtazapine	15.3495	11.328	-4.02153	(-6.6,-1.44)	0.0022	-26.20%
Prazosin	16.5418	11.8467	-4.69516	(-6.64,-2.75)	<.0001	-28.38%
Tricyclics	14.0854	12.1619	-1.92348	(-7.09,3.25)	0.4659	-13.66%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	998	847
Mirtazapine	1354	1021
Prazosin	2604	1867
Tricyclics	311	275

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	21.1893	16.7086	-4.48066	(-14.81,5.85)	0.3951	-21.15%	<.0001
Mirtazapine	17.234	14.3183	-2.91572	(-8.61,2.78)	0.316	-16.92%	0.0014
Prazosin	18.1949	15.5843	-2.61063	(-6.63,1.41)	0.2026	-14.35%	<.0001
Tricyclics	14.5596	13.4669	-1.09262	(-7.96,5.77)	0.7551	-7.51%	0.5303

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	5935	5247
Mirtazapine	5021	4007
Prazosin	13549	9494
Tricyclics	2033	1802

Changes in Suicidal Thought (% endorsing) by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: >=65	0.68557	(-15.65,17.02)	0.78783	(-9.31,10.89)	1.04933	(-14.57,16.66)
Mirtazapine: <65	1.56494	(-1.44,4.57)	1.43678	(-1.36,4.23)	1.3586	(-1.41,4.13)
<b>p-value for 3-way interaction</b>	0.74854		0.80157		0.8036	
Prazosin: >=65	0.01194	(-0.13,0.15)	0.12915	(-2.38,2.64)	0.61523	(-29.76,30.99)
Prazosin: <65	1.87003	(-0.08,3.82)	1.60572	(-0.19,3.41)	1.48331	(-0.64,3.61)
<b>p-value for 3-way interaction</b>	0.41063		0.47187		0.58209	
Tricyclics: >=65	2.78362	(-4.52,10.09)	2.63329	(-4.09,9.36)	3.66225	(-1.17,8.49)
Tricyclics: <65	3.38803	(0.15,6.63)	3.18958	(0.29,6.08)	2.72104	(0.49,4.95)
<b>p-value for 3-way interaction</b>	0.98015		0.96332		0.6417	
<b>overall 3-way interaction p-value</b>	0.8484		0.89312		0.78979	

**Changes in Suicidal Thought (% endorsing) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	19.9024	16.1972	-3.7052	(-6.19,-1.22)	0.0035	-18.62%
Mirtazapine	15.4642	13.5949	-1.86927	(-4.63,0.89)	0.1844	-12.09%
Prazosin	16.2322	14.9817	-1.25052	(-2.67,0.17)	0.0836	-7.70%
Tricyclics	13.6686	13.4202	-0.2484	(-4.31,3.81)	0.9045	-1.82%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	1854	1464
Mirtazapine	1320	925
Prazosin	5616	3621
Tricyclics	580	419

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	20.9795	16.1963	-4.78324	(-7.23,-2.33)	0.0001	-22.80%	0.517
Mirtazapine	17.1914	13.7372	-3.45413	(-7.45,0.54)	0.0905	-20.09%	0.2796
Prazosin	18.8324	14.9646	-3.86784	(-7.39,-0.34)	0.0316	-20.54%	0.0086
Tricyclics	14.7689	13.2623	-1.50662	(-12.75,9.73)	0.7928	-10.20%	0.7041

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	5079	4630
Mirtazapine	5055	4103
Prazosin	10537	7740
Tricyclics	1764	1658

Changes in Suicidal Thought (% endorsing) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: OEF/OIF	1.83593	(-3.29,6.97)	1.69942	(-2.88,6.28)	2.01764	(-2.29,6.33)
Mirtazapine: other era	1.3291	(-2.35,5)	1.17305	(-2.19,4.53)	1.04641	(-2.7,4.79)
p-value for 3-way interaction	0.76522		0.74004		0.59791	
Prazosin: OEF/OIF	2.45469	(-0.69,5.6)	2.2823	(-0.52,5.08)	2.57503	(-0.88,6.03)
Prazosin: other era	0.9154	(-1.8,3.63)	0.72765	(-1.9,3.36)	0.76221	(-2.12,3.64)
p-value for 3-way interaction	0.33566		0.27907		0.32578	
Tricyclics: OEF/OIF	3.4568	(-2.3,9.21)	3.39183	(-1.65,8.44)	2.7762	(-1.24,6.79)
Tricyclics: other era	3.27662	(-0.22,6.77)	3.03014	(-0.13,6.19)	2.8119	(0.45,5.17)
p-value for 3-way interaction	0.8654		0.78469		0.99399	
overall 3-way interaction p-value	0.79925		0.74114		0.72632	



**Changes in Suicidal Plan (% endorsing) by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	11.8627	10.0991	-1.76361	(-3.76,0.24)	0.084	-14.87%
Mirtazapine	10.1037	10.3395	0.23579	(-1.8,2.28)	0.8208	2.33%
Prazosin	10.0925	8.9101	-1.18243	(-2.5,0.14)	0.0797	-11.72%
Tricyclics	9.5338	7.9184	-1.61545	(-4.93,1.69)	0.3389	-16.94%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	1969	1539
Mirtazapine	1846	1340
Prazosin	4323	2903
Tricyclics	572	494

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	12.3574	10.1916	-2.16574	(-8.53,4.2)	0.5051	-17.53%	0.8665
Mirtazapine	8.4291	7.6923	-0.73681	(-2.23,0.75)	0.3331	-8.74%	0.2049
Prazosin	10.765	12.1141	1.34911	(-1.02,3.72)	0.2639	12.53%	0.0858
Tricyclics	3.6218	7.2727	3.65093	(-5.62,12.92)	0.4403	100.80%	0.0659

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	209	164
Mirtazapine	174	143
Prazosin	451	273
Tricyclics	130	110

**Changes in Suicidal Plan (% endorsing) by Augmenting Medication Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: male	1.9994	(-0.93,4.93)	1.86475	(-0.82,4.55)	1.56131	(-1.2,4.32)
Mirtazapine: female	1.42893	(-10.69,13.55)	1.14535	(-9.12,11.41)	0.38566	(-18.01,18.78)
<b>p-value for 3-way interaction</b>	0.86733		0.85196		0.76622	
Prazosin: male	0.58118	(-2.88,4.05)	0.17005	(-13.82,14.16)	0.12124	(-47.3,47.54)
Prazosin: female	3.51485	(-4.19,11.22)	3.03459	(-3.78,9.85)	2.4908	(-5.75,10.73)
<b>p-value for 3-way interaction</b>	0.45719		0.41211		0.578	
Tricyclics: male	0.14817	(-2.86,3.16)	-0.12943	(-1.68,1.42)	-1.1724	(-3.1,0.76)
Tricyclics: female	5.81667	(-1.99,13.62)	5.52187	(-1.52,12.56)	4.72644	(-0.87,10.32)
<b>p-value for 3-way interaction</b>	0.1593		0.13314		0.05548	
<b>overall 3-way interaction p-value</b>	0.44558		0.37668		0.18037	

**Changes in Suicidal Plan (% endorsing) by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	10.5486	8.8259	-1.72267	(-6.76,3.31)	0.5027	-16.33%
Mirtazapine	8.0669	8.2313	0.16441	(-3.76,4.09)	0.9345	2.04%
Prazosin	8.7757	6.0595	-2.71625	(-5.64,0.21)	0.0687	-30.95%
Tricyclics	12.4074	6.7901	-5.61728	(-14.44,3.21)	0.2124	-45.27%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	300	203
Mirtazapine	417	280
Prazosin	761	466
Tricyclics	90	81

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	12.1277	10.2815	-1.84616	(-26.62,22.93)	0.8839	-15.22%	0.3004
Mirtazapine	10.4518	10.5155	0.06372	(-0.02,0.15)	0.1324	0.61%	0.0599
Prazosin	10.4178	9.723	-0.69477	(-2.34,0.95)	0.4091	-6.67%	0.0028
Tricyclics	7.8554	7.9573	0.10191	(-0.04,0.24)	0.1555	1.30%	0.5672

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	1878	1500
Mirtazapine	1603	1203
Prazosin	4013	2710
Tricyclics	612	523

Changes in Suicidal Plan (% endorsing) by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: >=65	1.88708	(-4.88,8.65)	1.96893	(-4.01,7.95)	0.38527	(-8.87,9.65)
Mirtazapine: <65	1.90988	(-1.18,5)	1.72169	(-1.1,4.54)	1.63127	(-1.26,4.52)
p-value for 3-way interaction	0.95083		0.87489		0.74522	
Prazosin: >=65	-0.99359	(-4.56,2.58)	-1.14335	(-4.7,2.42)	-1.25665	(-5.85,3.33)
Prazosin: <65	1.1514	(-1.58,3.88)	0.72973	(-1.83,3.29)	0.63984	(-2.43,3.71)
p-value for 3-way interaction	0.42893		0.43505		0.51862	
Tricyclics: >=65	-3.89462	(-13.69,5.9)	-3.46333	(-13.01,6.08)	-7.17459	(-12.84,-1.51)
Tricyclics: <65	1.94807	(-2.56,6.45)	1.61504	(-2.37,5.6)	0.65157	(-4.41,5.72)
p-value for 3-way interaction	0.30038		0.34084		0.01602	
overall 3-way interaction p-value	0.59816		0.59391		0.08574	

**Changes in Suicidal Plan (% endorsing) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	10.8119	7.7979	-3.01395	(-6.53,0.5)	0.0932	-27.88%
Mirtazapine	10.1385	10.8696	0.73103	(-3.77,5.24)	0.7505	7.21%
Prazosin	9.3176	9.9742	0.65656	(-1.58,2.89)	0.5653	7.05%
Tricyclics	7.6923	9.5833	1.89103	(-4.57,8.35)	0.5662	24.58%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	1596	1289
Mirtazapine	1623	1207
Prazosin	3243	2179
Tricyclics	546	484

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	12.3107	10.85	-1.46073	(-112.5,109.58)	0.9794	-11.87%	0.0353
Mirtazapine	9.9156	9.9046	-0.011	(-0.16,0.14)	0.8878	-0.11%	0.638
Prazosin	10.5518	8.8246	-1.72723	(-7.96,4.51)	0.5873	-16.37%	0.9893
Tricyclics	8.6523	7.3588	-1.2935	(-19.02,16.43)	0.8863	-14.95%	0.7362

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	582	414
Mirtazapine	397	276
Prazosin	1531	997
Tricyclics	156	120

Changes in Suicidal Plan (% endorsing) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: OEF/OIF	3.74498	(-1.72,9.21)	3.51493	(-1.53,8.56)	3.37416	(-1.54,8.29)
Mirtazapine: other era	1.44973	(-1.87,4.77)	1.26123	(-1.68,4.2)	0.84715	(-2.38,4.07)
p-value for 3-way interaction	0.41801		0.40318		0.35327	
Prazosin: OEF/OIF	3.67051	(-0.52,7.86)	3.15787	(-0.64,6.95)	3.24101	(-1.44,7.92)
Prazosin: other era	-0.2665	(-1.64,1.1)	-0.64628	(-2.56,1.27)	-0.66147	(-3.14,1.82)
p-value for 3-way interaction	0.09263		0.08097		0.15034	
Tricyclics: OEF/OIF	4.90497	(-2.56,12.37)	4.9546	(-2.08,11.99)	4.15239	(-0.69,9)
Tricyclics: other era	0.16722	(-2.28,2.62)	-0.15191	(-1.6,1.29)	-2.11258	(-4.36,0.13)
p-value for 3-way interaction	0.23004		0.18827		0.01792	
overall 3-way interaction p-value	0.35664		0.30931		0.11888	

**Changes in Weight (pounds) by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	208.76	210.77	2.00955	(2.009,2.025)	<.0001	0.96%
Mirtazapine	203.8	206.62	2.81652	(2.816,2.832)	<.0001	1.38%
Prazosin	217.42	218.84	1.42576	(1.425,1.441)	<.0001	0.66%
Tricyclics	217.38	219.17	1.79743	(1.796,1.812)	<.0001	0.83%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	27908	27575
Mirtazapine	21784	21438
Prazosin	45495	44466
Tricyclics	8566	8435

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	177.4	180.83	3.42291	(3.422,3.438)	<.0001	1.93%	<.0001
Mirtazapine	171.16	175.91	4.75606	(4.755,4.771)	<.0001	2.78%	<.0001
Prazosin	182.48	184.49	2.0099	(2.009,2.025)	<.0001	1.10%	0.0003
Tricyclics	181.35	184.73	3.3821	(3.381,3.397)	<.0001	1.87%	<.0001

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	2384	2374
Mirtazapine	2049	2015
Prazosin	3963	3903
Tricyclics	1819	1791

**Changes in Weight (pounds) by Augmenting Medication Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: male</b>	0.58224	(0.429,0.736)	0.58267	(0.429,0.736)	0.67324	(0.496,0.85)
<b>Antipsychotics: female</b>	1.41167	(0.89,1.933)	1.41149	(0.89,1.933)	1.58073	(1.014,2.147)
<b>p-value for 3-way interaction</b>	0.00279		0.00281		0.00274	
<b>Mirtazapine: male</b>	1.38932	(1.223,1.555)	1.3901	(1.224,1.556)	1.71226	(1.535,1.89)
<b>Mirtazapine: female</b>	2.74388	(2.195,3.293)	2.74389	(2.195,3.293)	3.21596	(2.649,3.783)
<b>p-value for 3-way interaction</b>	0		0		0	
<b>Tricyclics: male</b>	0.37124	(0.135,0.607)	0.37154	(0.136,0.607)	0.60028	(0.423,0.778)
<b>Tricyclics: female</b>	1.37184	(0.804,1.939)	1.3708	(0.803,1.938)	1.83547	(1.273,2.398)
<b>p-value for 3-way interaction</b>	0.00142		0.00144		0.00004	
<b>overall 3-way interaction p-value</b>	<0.0001		<0.0001		<0.0001	



**Changes in Weight (pounds) by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	200.91	200.6	-0.31156	(-0.313,-0.297)	0.04	-0.16%
Mirtazapine	197.72	198.78	1.06195	(1.061,1.077)	<.0001	0.54%
Prazosin	213.28	213.32	0.04439	(0.043,0.059)	0.6503	0.02%
Tricyclics	214.43	214.53	0.09705	(0.096,0.112)	0.6994	0.05%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	5077	4919
Mirtazapine	5551	5484
Prazosin	9731	9608
Tricyclics	1599	1571

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	207.34	209.94	2.60778	(2.607,2.623)	<.0001	1.26%	<.0001
Mirtazapine	201.96	205.53	3.57582	(3.575,3.591)	<.0001	1.77%	<.0001
Prazosin	214.92	216.75	1.83301	(1.832,1.848)	<.0001	0.85%	<.0001
Tricyclics	210.47	212.9	2.43527	(2.434,2.45)	<.0001	1.16%	<.0001

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	25215	25030
Mirtazapine	18282	17969
Prazosin	39727	38761
Tricyclics	8786	8655

**Changes in Weight (pounds) by Augmenting Medication Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: &gt;=65</b>	-0.35844	(-0.705,-0.012)	-0.35636	(-0.703,-0.01)	0.03101	(-0.351,0.413)
<b>Antipsychotics: &lt;65</b>	0.77376	(0.612,0.936)	0.77511	(0.613,0.937)	0.91514	(0.727,1.103)
<b>p-value for 3-way interaction</b>	0		0		0.00005	
<b>Mirtazapine: &gt;=65</b>	1.01665	(0.682,1.351)	1.01746	(0.683,1.352)	1.36382	(0.983,1.745)
<b>Mirtazapine: &lt;65</b>	1.74126	(1.561,1.921)	1.74278	(1.563,1.923)	1.96139	(1.773,2.15)
<b>p-value for 3-way interaction</b>	0.00019		0.00018		0.00585	
<b>Tricyclics: &gt;=65</b>	0.05057	(-0.487,0.588)	0.05195	(-0.485,0.589)	0.34455	(-0.042,0.731)
<b>Tricyclics: &lt;65</b>	0.60238	(0.367,0.838)	0.60403	(0.369,0.839)	0.7754	(0.588,0.963)
<b>p-value for 3-way interaction</b>	0.06517		0.06502		0.04927	
<b>overall 3-way interaction p-value</b>	<0.0001		<0.0001		0.00059	

**Changes in Weight (pounds) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Othe Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	202.69	206.67	3.98311	(3.982,3.998)	<.0001	1.97%
Mirtazapine	200.33	205.02	4.69097	(4.69,4.706)	<.0001	2.34%
Prazosin	210.49	213.35	2.85649	(2.856,2.871)	<.0001	1.36%
Tricyclics	201.94	205.14	3.20555	(3.205,3.221)	<.0001	1.59%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	5350	5201
Mirtazapine	3653	3477
Prazosin	13339	12763
Tricyclics	1649	1606

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	207.07	208.81	1.74247	(1.741,1.757)	<.0001	0.84%	<.0001
Mirtazapine	201.1	203.79	2.69504	(2.694,2.71)	<.0001	1.34%	<.0001
Prazosin	216.15	217.15	0.99233	(0.991,1.007)	<.0001	0.46%	<.0001
Tricyclics	212.83	214.7	1.86832	(1.867,1.883)	<.0001	0.88%	<.0001

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	24942	24748
Mirtazapine	20180	19976
Prazosin	36119	35606
Tricyclics	8736	8620

**Changes in Weight (pounds) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Othe Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: OEF/OIF</b>	1.12491	(0.792,1.458)	1.12413	(0.791,1.457)	1.06313	(0.685,1.441)
<b>Antipsychotics: other era</b>	0.74912	(0.584,0.914)	0.75	(0.585,0.915)	0.77648	(0.588,0.965)
<b>p-value for 3-way interaction</b>	0.0475		0.04846		0.1837	
<b>Mirtazapine: OEF/OIF</b>	1.83304	(1.447,2.22)	1.83556	(1.449,2.222)	1.86388	(1.488,2.24)
<b>Mirtazapine: other era</b>	1.70149	(1.526,1.877)	1.70192	(1.526,1.877)	1.92635	(1.737,2.116)
<b>p-value for 3-way interaction</b>	0.54357		0.53716		0.7713	
<b>Tricyclics: OEF/OIF</b>	0.34995	(-0.179,0.879)	0.35209	(-0.177,0.881)	0.35868	(-0.017,0.735)
<b>Tricyclics: other era</b>	0.87564	(0.638,1.113)	0.87611	(0.639,1.113)	0.87827	(0.689,1.068)
<b>p-value for 3-way interaction</b>	0.0755		0.07642		0.01554	
<b>overall 3-way interaction p-value</b>	0.02953		0.03032		0.00345	

### Changes in A1c by Augmenting Medication Group - Male vs. Female

#### Male

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	6.2371	6.2619	0.02481	(0.024,0.04)	0.0019	0.40%
Mirtazapine	6.3025	6.4439	0.14139	(0.14,0.156)	<.0001	2.24%
Prazosin	6.294	6.3052	0.01121	(0.01,0.026)	0.0546	0.18%
Tricyclics	6.5315	6.6117	0.08019	(0.079,0.095)	<.0001	1.23%

#### Number of Windows - Male

Medications	n(pre)	n(post)
Antipsychotics	14406	16412
Mirtazapine	11786	11938
Prazosin	25222	25310
Tricyclics	5085	5095

#### Female

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	5.7845	5.8714	0.08696	(0.086,0.102)	0.0064	1.50%	0.0587
Mirtazapine	5.8749	6.0448	0.1699	(0.169,0.185)	<.0001	2.89%	0.4522
Prazosin	5.8515	5.8718	0.02033	(0.019,0.035)	0.3932	0.35%	0.7098
Tricyclics	5.9693	6.0583	0.08896	(0.088,0.104)	0.0343	1.49%	0.8437

#### Number of Windows - Female

Medications	n(pre)	n(post)
Antipsychotics	1002	1177
Mirtazapine	873	868
Prazosin	1763	1750
Tricyclics	712	742

Changes in A1c by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: male</b>	0.01451	(-0.005,0.034)	0.02478	(0.005,0.044)	0.02161	(-0.001,0.044)
<b>Antipsychotics: female</b>	0.06699	(-0.012,0.146)	0.07301	(-0.005,0.151)	0.0613	(-0.024,0.146)
<b>p-value for 3-way interaction</b>	0.20831		0.24095		0.37709	
<b>Mirtazapine: male</b>	0.12997	(0.109,0.151)	0.13121	(0.11,0.152)	0.13833	(0.116,0.161)
<b>Mirtazapine: female</b>	0.14921	(0.065,0.234)	0.14856	(0.065,0.232)	0.12854	(0.041,0.216)
<b>p-value for 3-way interaction</b>	0.66574		0.69294		0.83241	
<b>Tricyclics: male</b>	0.06865	(0.04,0.097)	0.06949	(0.041,0.098)	0.09074	(0.068,0.113)
<b>Tricyclics: female</b>	0.06797	(-0.021,0.157)	0.07297	(-0.015,0.161)	0.07095	(-0.017,0.159)
<b>p-value for 3-way interaction</b>	0.98867		0.94121		0.67067	
<b>overall 3-way interaction p-value</b>	0.61539		0.68509		0.59262	

**Changes in A1c by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	6.4321	6.4261	-0.00607	(-0.007,0.009)	0.7166	-0.09%
Mirtazapine	6.4176	6.5222	0.10468	(0.104,0.12)	<.0001	1.63%
Prazosin	6.4792	6.4749	-0.00433	(-0.005,0.011)	0.6926	-0.07%
Tricyclics	6.5846	6.6275	0.04288	(0.042,0.058)	0.156	0.65%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	3141	3330
Mirtazapine	3499	3496
Prazosin	6573	6584
Tricyclics	1133	1134

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	6.1522	6.1912	0.03901	(0.038,0.054)	<.0001	0.63%	0.0169
Mirtazapine	6.2174	6.3771	0.15964	(0.159,0.175)	<.0001	2.57%	0.0053
Prazosin	6.1982	6.2159	0.0177	(0.017,0.033)	0.0074	0.29%	0.0851
Tricyclics	6.4237	6.5141	0.09039	(0.089,0.105)	<.0001	1.41%	0.1617

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	12267	14259
Mirtazapine	9160	9310
Prazosin	20412	20476
Tricyclics	4664	4703

Changes in A1c by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: &gt;=65</b>	-0.00081	(-0.041,0.039)	0.00899	(-0.03,0.048)	0.01048	(-0.033,0.054)
<b>Antipsychotics: &lt;65</b>	0.02214	(0,0.044)	0.03145	(0.01,0.053)	0.02965	(0.005,0.055)
<b>p-value for 3-way interaction</b>	0.3209		0.32682		0.45306	
<b>Mirtazapine: &gt;=65</b>	0.10921	(0.071,0.148)	0.11182	(0.074,0.15)	0.11378	(0.07,0.157)
<b>Mirtazapine: &lt;65</b>	0.14158	(0.117,0.166)	0.14135	(0.117,0.165)	0.1463	(0.121,0.172)
<b>p-value for 3-way interaction</b>	0.16283		0.19901		0.20748	
<b>Tricyclics: &gt;=65</b>	0.04716	(-0.011,0.106)	0.04525	(-0.013,0.103)	0.0515	(0.008,0.095)
<b>Tricyclics: &lt;65</b>	0.07223	(0.042,0.103)	0.07544	(0.045,0.106)	0.10121	(0.076,0.126)
<b>p-value for 3-way interaction</b>	0.45641		0.36586		0.05204	
<b>overall 3-way interaction p-value</b>	0.49839		0.51776		0.25686	



**Changes in A1c by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	5.601	5.669	0.06799	(0.067,0.083)	0.0061	1.21%
Mirtazapine	5.6351	5.7907	0.15567	(0.155,0.171)	<.0001	2.76%
Prazosin	5.7315	5.7828	0.05133	(0.05,0.066)	0.0004	0.90%
Tricyclics	5.715	5.7929	0.07787	(0.077,0.093)	0.1286	1.36%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	1824	2259
Mirtazapine	1275	1213
Prazosin	5135	5044
Tricyclics	543	561

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	6.3029	6.3283	0.02539	(0.024,0.04)	0.0018	0.40%	0.1022
Mirtazapine	6.3527	6.4934	0.14073	(0.14,0.156)	<.0001	2.22%	0.6609
Prazosin	6.4059	6.4101	0.00418	(0.003,0.019)	0.4952	0.07%	0.0028
Tricyclics	6.5472	6.6285	0.08126	(0.08,0.096)	<.0001	1.24%	0.9493

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	13584	15330
Mirtazapine	11384	11593
Prazosin	21850	22016
Tricyclics	5254	5276

Changes in A1c by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: OEF/OIF</b>	0.01678	(-0.04,0.074)	0.02207	(-0.034,0.078)	0.01868	(-0.046,0.083)
<b>Antipsychotics: other era</b>	0.02222	(0.002,0.043)	0.03072	(0.011,0.051)	0.02768	(0.005,0.051)
<b>p-value for 3-way interaction</b>	0.86006		0.7767		0.79632	
<b>Mirtazapine: OEF/OIF</b>	0.10402	(0.036,0.172)	0.10518	(0.038,0.173)	0.10693	(0.041,0.173)
<b>Mirtazapine: other era</b>	0.13645	(0.115,0.158)	0.13752	(0.116,0.159)	0.14139	(0.118,0.165)
<b>p-value for 3-way interaction</b>	0.37611		0.37061		0.33496	
<b>Tricyclics: OEF/OIF</b>	0.02644	(-0.069,0.122)	0.02974	(-0.065,0.124)	0.03917	(-0.028,0.107)
<b>Tricyclics: other era</b>	0.07683	(0.048,0.105)	0.07694	(0.049,0.105)	0.09712	(0.074,0.12)
<b>p-value for 3-way interaction</b>	0.32348		0.34857		0.11179	
<b>overall 3-way interaction p-value</b>	0.66795		0.68974		0.3929	

### Changes in Glucose by Augmenting Medication Group - Male vs. Female

#### Male

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	113.49	115	1.51243	(1.511,1.527)	<.0001	1.33%
Mirtazapine	114.39	118.17	3.7829	(3.782,3.798)	<.0001	3.31%
Prazosin	113.6	115.32	1.7171	(1.716,1.732)	<.0001	1.51%
Tricyclics	120.1	122.71	2.61243	(2.611,2.627)	<.0001	2.18%

#### Number of Windows - Male

Medications	n(pre)	n(post)
Antipsychotics	25395	25123
Mirtazapine	20126	19469
Prazosin	40872	39298
Tricyclics	7908	7699

#### Female

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	98.9133	101.2	2.28553	(2.285,2.301)	0.0085	2.31%	0.3917
Mirtazapine	101.26	103.62	2.36179	(2.361,2.377)	0.0113	2.33%	0.1436
Prazosin	99.7709	101.69	1.92371	(1.923,1.939)	0.0037	1.93%	0.7641
Tricyclics	100.99	103.38	2.39129	(2.39,2.406)	0.023	2.37%	0.848

#### Number of Windows - Female

Medications	n(pre)	n(post)
Antipsychotics	2116	2086
Mirtazapine	1830	1728
Prazosin	3420	3267
Tricyclics	1640	1580

Changes in Glucose by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: male</b>	-0.20772	(-0.819,0.404)	-0.05276	(-0.661,0.555)	-0.01987	(-0.728,0.688)
<b>Antipsychotics: female</b>	0.36448	(-1.78,2.509)	0.41487	(-1.716,2.546)	0.40977	(-1.922,2.742)
<b>p-value for 3-way interaction</b>	0.61497		0.67915		0.72971	
<b>Mirtazapine: male</b>	2.07339	(1.414,2.733)	2.08267	(1.427,2.739)	2.1875	(1.478,2.897)
<b>Mirtazapine: female</b>	0.44822	(-1.816,2.712)	0.39434	(-1.855,2.644)	0.24229	(-2.108,2.593)
<b>p-value for 3-way interaction</b>	0.17677		0.15793		0.12046	
<b>Tricyclics: male</b>	0.8969	(-0.038,1.832)	0.89342	(-0.037,1.824)	0.85737	(0.144,1.57)
<b>Tricyclics: female</b>	0.4685	(-1.853,2.79)	0.52157	(-1.787,2.83)	0.27488	(-2.053,2.603)
<b>p-value for 3-way interaction</b>	0.73725		0.76965		0.63912	
<b>overall 3-way interaction p-value</b>	0.3883		0.38897		0.24377	

**Changes in Glucose by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	118.94	120.39	1.45056	(1.45,1.466)	0.0108	1.22%
Mirtazapine	118.18	121.95	3.76038	(3.759,3.775)	<.0001	3.18%
Prazosin	119.96	120.83	0.87021	(0.869,0.885)	0.0249	0.73%
Tricyclics	123.57	124.78	1.2022	(1.201,1.217)	0.26	0.97%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	4765	4634
Mirtazapine	5233	5113
Prazosin	9163	8978
Tricyclics	1519	1502

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	111.02	112.63	1.60944	(1.608,1.624)	<.0001	1.45%	0.7999
Mirtazapine	111.77	115.41	3.64246	(3.641,3.657)	<.0001	3.26%	0.8473
Prazosin	110.63	112.59	1.95733	(1.956,1.972)	<.0001	1.77%	0.0132
Tricyclics	115.51	118.36	2.84601	(2.845,2.861)	<.0001	2.46%	0.1591

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	22746	22575
Mirtazapine	16723	16084
Prazosin	35129	33587
Tricyclics	8029	7777

**Changes in Glucose by Augmenting Medication Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: &gt;=65</b>	0.57921	(-0.769,1.928)	0.81058	(-0.532,2.153)	0.91518	(-0.576,2.406)
<b>Antipsychotics: &lt;65</b>	-0.35045	(-1.005,0.304)	-0.23292	(-0.883,0.418)	-0.20223	(-0.963,0.558)
<b>p-value for 3-way interaction</b>	0.22405		0.17047		0.19069	
<b>Mirtazapine: &gt;=65</b>	2.88941	(1.584,4.194)	2.94633	(1.647,4.246)	3.09808	(1.608,4.588)
<b>Mirtazapine: &lt;65</b>	1.69658	(0.972,2.421)	1.6802	(0.96,2.4)	1.7486	(0.985,2.512)
<b>p-value for 3-way interaction</b>	0.11723		0.09493		0.1141	
<b>Tricyclics: &gt;=65</b>	0.33168	(-1.744,2.408)	0.23382	(-1.834,2.302)	0.86023	(-0.648,2.368)
<b>Tricyclics: &lt;65</b>	0.89333	(-0.053,1.84)	0.94687	(0.005,1.889)	0.78136	(0.017,1.546)
<b>p-value for 3-way interaction</b>	0.62946		0.53857		0.92715	
<b>overall 3-way interaction p-value</b>	0.26646		0.18039		0.26572	

## Changes in Glucose by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

### Iraq and Afghanistan Era

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	96.8829	99.3177	2.43473	(2.434,2.45)	<.0001	2.51%
Mirtazapine	97.6779	100.89	3.21118	(3.21,3.226)	<.0001	3.29%
Prazosin	99.4175	101.68	2.26327	(2.262,2.278)	<.0001	2.28%
Tricyclics	98.1234	99.5784	1.45504	(1.454,1.47)	0.2192	1.48%

### Number of Windows - Iraq and Afghanistan Era

Medications	n(pre)	n(post)
Antipsychotics	4502	4285
Mirtazapine	3118	2774
Prazosin	11069	10054
Tricyclics	1402	1294

### Other Era

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	115.55	116.92	1.36714	(1.366,1.382)	<.0001	1.18%	0.11
Mirtazapine	116	119.66	3.65876	(3.658,3.674)	<.0001	3.15%	0.5745
Prazosin	117.13	118.59	1.46593	(1.465,1.481)	<.0001	1.25%	0.0653
Tricyclics	120.19	122.87	2.68552	(2.685,2.701)	<.0001	2.23%	0.3333

### Number of Windows - Other Era

Medications	n(pre)	n(post)
Antipsychotics	23009	22924
Mirtazapine	18838	18423
Prazosin	33223	32511
Tricyclics	8146	7985

**Changes in Glucose by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: OEF/OIF</b>	0.17482	(-1.241,1.591)	0.17337	(-1.233,1.58)	-0.00465	(-1.619,1.61)
<b>Antipsychotics: other era</b>	-0.09905	(-0.748,0.55)	0.01647	(-0.63,0.663)	0.09324	(-0.653,0.839)
<b>p-value for 3-way interaction</b>	0.73041		0.84254		0.91408	
<b>Mirtazapine: OEF/OIF</b>	0.95128	(-0.697,2.6)	0.97577	(-0.661,2.613)	0.93507	(-0.681,2.551)
<b>Mirtazapine: other era</b>	2.19817	(1.508,2.889)	2.18586	(1.498,2.874)	2.2626	(1.514,3.011)
<b>p-value for 3-way interaction</b>	0.17152		0.18173		0.144	
<b>Tricyclics: OEF/OIF</b>	-0.80551	(-3.072,1.461)	-0.83928	(-3.092,1.413)	-0.80381	(-2.433,0.825)
<b>Tricyclics: other era</b>	1.22246	(0.289,2.155)	1.19311	(0.263,2.123)	1.15432	(0.404,1.905)
<b>p-value for 3-way interaction</b>	0.10488		0.10213		0.03235	
<b>overall 3-way interaction p-value</b>	0.18521		0.21246		0.0933	



**Changes in Triglycerides by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	171.68	179.45	7.7614	(7.76,7.776)	<.0001	4.52%
Mirtazapine	165.8	180.25	14.4562	(14.455,14.471)	<.0001	8.72%
Prazosin	174.66	174.78	0.1287	(0.128,0.144)	0.8299	0.07%
Tricyclics	187.2	191.78	4.5758	(4.575,4.591)	0.001	2.44%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	23432	23414
Mirtazapine	18697	17823
Prazosin	38061	36205
Tricyclics	7354	7070

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	136.01	146.3	10.2956	(10.295,10.311)	0.0004	7.57%	0.4015
Mirtazapine	139.14	150.31	11.1679	(11.167,11.183)	0.0006	8.03%	0.3299
Prazosin	132.29	132.49	0.1954	(0.194,0.21)	0.9317	0.15%	0.9774
Tricyclics	138.33	142.8	4.4682	(4.467,4.483)	0.1771	3.23%	0.9761

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	1819	1833
Mirtazapine	1597	1473
Prazosin	2906	2707
Tricyclics	1395	1312

Changes in Triglycerides by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: male</b>	7.522	(5.57,9.474)	7.5278	(5.577,9.478)	7.8776	(5.641,10.114)
<b>Antipsychotics: female</b>	10.0412	(2.781,17.301)	9.8728	(2.626,17.12)	9.559	(1.73,17.388)
<b>p-value for 3-way interaction</b>	0.5113		0.5402		0.6856	
<b>Mirtazapine: male</b>	14.2393	(12.129,16.349)	14.1453	(12.037,16.253)	15.1239	(12.877,17.371)
<b>Mirtazapine: female</b>	10.8865	(3.219,18.554)	10.6059	(2.951,18.261)	11.4803	(3.568,19.393)
<b>p-value for 3-way interaction</b>	0.4086		0.3823		0.3853	
<b>Tricyclics: male</b>	4.4701	(1.482,7.459)	4.4235	(1.437,7.41)	5.4705	(3.214,7.727)
<b>Tricyclics: female</b>	4.2344	(-3.741,12.21)	4.5965	(-3.366,12.559)	4.0988	(-3.795,11.993)
<b>p-value for 3-way interaction</b>	0.9567		0.9682		0.7433	
<b>overall 3-way interaction p-value</b>	0.61694		0.61091		0.61584	

### Changes in Triglycerides by Augmenting Medication Group - Age 65 and Over vs. Under 65

#### Age >=65

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	151.78	154.04	2.259	(2.258,2.274)	0.2179	1.49%
Mirtazapine	149.05	159.41	10.3603	(10.359,10.375)	<.0001	6.95%
Prazosin	158.06	155.71	-2.353	(-2.354,-2.338)	0.0546	-1.49%
Tricyclics	169.3	171.9	2.5945	(2.594,2.61)	0.4018	1.53%

#### Number of Windows - Age >=65

Medications	n(pre)	n(post)
Antipsychotics	4430	4237
Mirtazapine	4927	4652
Prazosin	8662	8410
Tricyclics	1432	1403

#### Age <65

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	172.53	181.56	9.0308	(9.03,9.046)	<.0001	5.23%	0.0008
Mirtazapine	168.14	183.64	15.4936	(15.493,15.509)	<.0001	9.22%	0.012
Prazosin	174.91	175.82	0.9147	(0.914,0.93)	0.1648	0.52%	0.0187
Tricyclics	180.96	185.99	5.0308	(5.03,5.046)	0.0004	2.78%	0.4735

#### Number of Windows - Age <65

Medications	n(pre)	n(post)
Antipsychotics	20821	21010
Mirtazapine	15367	14644
Prazosin	32305	30502
Tricyclics	7317	6979

**Changes in Triglycerides by Augmenting Medication Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: &gt;=65</b>	4.5676	(0.258,8.877)	4.7541	(0.449,9.06)	5.0416	(0.344,9.74)
<b>Antipsychotics: &lt;65</b>	7.9963	(5.894,10.098)	8.0916	(5.992,10.191)	8.5947	(6.175,11.014)
<b>p-value for 3-way interaction</b>	0.161		0.172		0.1875	
<b>Mirtazapine: &gt;=65</b>	12.6934	(8.532,16.855)	12.7408	(8.583,16.899)	12.8014	(8.106,17.497)
<b>Mirtazapine: &lt;65</b>	14.4651	(12.132,16.799)	14.3635	(12.033,16.694)	15.3608	(12.925,17.797)
<b>p-value for 3-way interaction</b>	0.4667		0.5046		0.343	
<b>Tricyclics: &gt;=65</b>	4.9908	(-1.586,11.568)	5.0232	(-1.549,11.595)	4.8023	(0.069,9.535)
<b>Tricyclics: &lt;65</b>	4.1369	(1.066,7.208)	4.1767	(1.109,7.244)	5.4917	(3.05,7.934)
<b>p-value for 3-way interaction</b>	0.8177		0.819		0.7997	
<b>overall 3-way interaction p-value</b>	0.49162		0.5193		0.52912	

## Changes in Triglycerides by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

### Iraq and Afghanistan Era

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	167.82	181.08	13.2614	(13.26,13.276)	<.0001	7.90%
Mirtazapine	165.84	185.72	19.8801	(19.879,19.895)	<.0001	11.99%
Prazosin	175.18	180.43	5.2515	(5.251,5.267)	<.0001	3.00%
Tricyclics	174.45	184.04	9.5937	(9.593,9.609)	0.0096	5.50%

### Number of Windows - Iraq and Afghanistan Era

Medications	n(pre)	n(post)
Antipsychotics	3897	3822
Mirtazapine	2707	2403
Prazosin	9683	8749
Tricyclics	1207	1065

### Other Era

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	169.18	176.24	7.0586	(7.058,7.074)	<.0001	4.17%	0.005
Mirtazapine	163.2	176.71	13.517	(13.516,13.532)	<.0001	8.28%	0.0204
Prazosin	170.11	168.96	-1.1514	(-1.152,-1.136)	0.0773	-0.68%	<.0001
Tricyclics	179.84	183.74	3.9041	(3.903,3.919)	0.0042	2.17%	0.1495

### Number of Windows - Other Era

Medications	n(pre)	n(post)
Antipsychotics	21354	21425
Mirtazapine	17587	16893
Prazosin	31284	30163
Tricyclics	7542	7317

Changes in Triglycerides by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: OEF/OIF</b>	7.9021	(3.19,12.615)	8.0403	(3.338,12.742)	8.6224	(3.305,13.94)
<b>Antipsychotics: other era</b>	8.1097	(6.042,10.177)	8.1473	(6.082,10.213)	8.0492	(5.695,10.403)
<b>p-value for 3-way interaction</b>	0.937		0.9674		0.8468	
<b>Mirtazapine: OEF/OIF</b>	14.4898	(8.987,19.992)	14.3327	(8.842,19.823)	14.4801	(9.136,19.824)
<b>Mirtazapine: other era</b>	14.5884	(12.382,16.795)	14.5203	(12.316,16.725)	15.1394	(12.773,17.506)
<b>p-value for 3-way interaction</b>	0.974		0.9505		0.825	
<b>Tricyclics: OEF/OIF</b>	4.5644	(-3.139,12.268)	4.5012	(-3.186,12.188)	7.6206	(2.182,13.06)
<b>Tricyclics: other era</b>	5.0518	(2.059,8.045)	5.1176	(2.127,8.108)	5.2434	(2.873,7.613)
<b>p-value for 3-way interaction</b>	0.908		0.8836		0.4322	
<b>overall 3-way interaction p-value</b>	0.99943		0.99909		0.7888	

**Changes in HDL Cholesterol by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	43.0437	42.5533	-0.49041	(-0.491,-0.475)	<.0001	-1.14%
Mirtazapine	43.7286	43.11	-0.6186	(-0.62,-0.604)	<.0001	-1.42%
Prazosin	43.0453	43.1096	0.06425	(0.063,0.079)	0.1503	0.15%
Tricyclics	41.3255	41.2243	-0.10119	(-0.102,-0.086)	0.3066	-0.25%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	23219	23263
Mirtazapine	18538	17705
Prazosin	37793	35994
Tricyclics	7316	7058

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	53.6752	53.6816	0.00644	(0.005,0.021)	0.9778	0.01%	0.0379
Mirtazapine	54.1729	53.7392	-0.43362	(-0.435,-0.419)	0.0875	-0.80%	0.4827
Prazosin	54.0104	54.5879	0.57745	(0.576,0.592)	0.0008	1.07%	0.0039
Tricyclics	52.7041	52.8053	0.10128	(0.1,0.116)	0.6708	0.19%	0.4326

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	1816	1831
Mirtazapine	1590	1474
Prazosin	2899	2694
Tricyclics	1389	1307

**Changes in HDL Cholesterol by Augmenting Medication Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: male</b>	-0.55119	(-0.7,-0.402)	-0.55523	(-0.704,-0.406)	-0.49608	(-0.668,-0.325)
<b>Antipsychotics: female</b>	-0.57079	(-1.129,-0.013)	-0.55908	(-1.116,-0.002)	-0.69643	(-1.301,-0.092)
<b>p-value for 3-way interaction</b>	0.94697		0.98954		0.53226	
<b>Mirtazapine: male</b>	-0.67893	(-0.84,-0.518)	-0.67289	(-0.833,-0.512)	-0.6866	(-0.859,-0.514)
<b>Mirtazapine: female</b>	-0.99849	(-1.588,-0.409)	-0.97452	(-1.563,-0.386)	-1.0963	(-1.708,-0.484)
<b>p-value for 3-way interaction</b>	0.30508		0.33225		0.20661	
<b>Tricyclics: male</b>	-0.16248	(-0.389,0.064)	-0.15901	(-0.386,0.068)	-0.16374	(-0.337,0.009)
<b>Tricyclics: female</b>	-0.46766	(-1.08,0.145)	-0.47586	(-1.088,0.136)	-0.55179	(-1.163,0.059)
<b>p-value for 3-way interaction</b>	0.35993		0.34115		0.23079	
<b>overall 3-way interaction p-value</b>	0.63694		0.63232		0.55604	



### Changes in HDL Cholesterol by Augmenting Medication Group - Age 65 and Over vs. Under 65

#### Age >=65

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	44.2837	44.02	-0.26368	(-0.265,-0.249)	0.0665	-0.60%
Mirtazapine	44.9275	44.517	-0.41048	(-0.411,-0.395)	0.0027	-0.91%
Prazosin	43.973	44.2631	0.29007	(0.289,0.305)	0.0014	0.66%
Tricyclics	43.0018	43.1596	0.15783	(0.157,0.173)	0.4729	0.37%

#### Number of Windows - Age >=65

Medications	n(pre)	n(post)
Antipsychotics	4404	4233
Mirtazapine	4892	4637
Prazosin	8613	8376
Tricyclics	1426	1401

#### Age <65

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	43.7677	43.2724	-0.49534	(-0.496,-0.48)	<.0001	-1.13%	0.1438
Mirtazapine	44.4859	43.8117	-0.67419	(-0.675,-0.659)	<.0001	-1.52%	0.0955
Prazosin	43.8601	43.8976	0.03756	(0.037,0.053)	0.446	0.09%	0.0143
Tricyclics	43.2718	43.1437	-0.12811	(-0.129,-0.113)	0.2033	-0.30%	0.2371

#### Number of Windows - Age <65

Medications	n(pre)	n(post)
Antipsychotics	20631	20861
Mirtazapine	15236	14542
Prazosin	32079	30312
Tricyclics	7279	6964

**Changes in HDL Cholesterol by Augmenting Medication Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: &gt;=65</b>	-0.54853	(-0.875,-0.222)	-0.55744	(-0.884,-0.231)	-0.48706	(-0.845,-0.129)
<b>Antipsychotics: &lt;65</b>	-0.53032	(-0.691,-0.369)	-0.53849	(-0.699,-0.378)	-0.50517	(-0.691,-0.319)
<b>p-value for 3-way interaction</b>	0.92187		0.91866		0.9299	
<b>Mirtazapine: &gt;=65</b>	-0.69901	(-1.014,-0.384)	-0.70016	(-1.015,-0.385)	-0.703	(-1.061,-0.345)
<b>Mirtazapine: &lt;65</b>	-0.70594	(-0.884,-0.528)	-0.69799	(-0.876,-0.52)	-0.71881	(-0.906,-0.531)
<b>p-value for 3-way interaction</b>	0.97011		0.99062		0.93888	
<b>Tricyclics: &gt;=65</b>	-0.13089	(-0.628,0.366)	-0.13128	(-0.628,0.365)	0.01209	(-0.348,0.372)
<b>Tricyclics: &lt;65</b>	-0.16211	(-0.396,0.072)	-0.16191	(-0.396,0.072)	-0.24404	(-0.432,-0.056)
<b>p-value for 3-way interaction</b>	0.91126		0.9129		0.21633	
<b>overall 3-way interaction p-value</b>	0.99852		0.99869		0.55408	

## Changes in HDL Cholesterol by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

### Iraq and Afghanistan Era

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	43.7672	43.3277	-0.43948	(-0.44,-0.424)	0.0077	-1.00%
Mirtazapine	44.1865	43.6528	-0.53378	(-0.535,-0.519)	0.0089	-1.21%
Prazosin	43.9573	43.8599	-0.09739	(-0.098,-0.082)	0.3131	-0.22%
Tricyclics	44.1605	43.9597	-0.20075	(-0.202,-0.186)	0.4559	-0.46%

### Number of Windows - Iraq and Afghanistan Era

Medications	n(pre)	n(post)
Antipsychotics	3876	3801
Mirtazapine	2686	2398
Prazosin	9626	8718
Tricyclics	1201	1069

### Other Era

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	43.8703	43.4125	-0.45781	(-0.459,-0.443)	<.0001	-1.04%	0.9176
Mirtazapine	44.6545	44.0357	-0.61884	(-0.62,-0.604)	<.0001	-1.39%	0.6944
Prazosin	43.8611	44.0051	0.14394	(0.143,0.159)	0.003	0.33%	0.0255
Tricyclics	43.0681	43.0077	-0.06043	(-0.061,-0.045)	0.5349	-0.14%	0.6241

### Number of Windows - Other Era

Medications	n(pre)	n(post)
Antipsychotics	21159	21293
Mirtazapine	17442	16781
Prazosin	31066	29970
Tricyclics	7504	7296

**Changes in HDL Cholesterol by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: OEF/OIF</b>	-0.34634	(-0.712,0.02)	-0.34381	(-0.709,0.022)	-0.36727	(-0.782,0.048)
<b>Antipsychotics: other era</b>	-0.59781	(-0.755,-0.44)	-0.60847	(-0.766,-0.451)	-0.53561	(-0.716,-0.355)
<b>p-value for 3-way interaction</b>	0.21614		0.19218		0.46595	
<b>Mirtazapine: OEF/OIF</b>	-0.42861	(-0.855,-0.002)	-0.41224	(-0.838,0.014)	-0.44013	(-0.857,-0.023)
<b>Mirtazapine: other era</b>	-0.75849	(-0.926,-0.591)	-0.75602	(-0.924,-0.588)	-0.77287	(-0.954,-0.592)
<b>p-value for 3-way interaction</b>	0.15866		0.14111		0.15169	
<b>Tricyclics: OEF/OIF</b>	-0.10638	(-0.703,0.49)	-0.10902	(-0.704,0.486)	-0.22362	(-0.649,0.201)
<b>Tricyclics: other era</b>	-0.20064	(-0.428,0.026)	-0.20111	(-0.428,0.026)	-0.19464	(-0.376,-0.013)
<b>p-value for 3-way interaction</b>	0.7722		0.77692		0.90215	
<b>overall 3-way interaction p-value</b>	0.42763		0.38332		0.39658	

**Changes in LDL Cholesterol by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	108.45	106.15	-2.30028	(-2.301,-2.285)	<.0001	-2.12%
Mirtazapine	105.03	103.59	-1.43979	(-1.441,-1.425)	<.0001	-1.37%
Prazosin	109.01	105.87	-3.13566	(-3.137,-3.121)	<.0001	-2.88%
Tricyclics	106.52	103.47	-3.05533	(-3.056,-3.04)	<.0001	-2.87%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	22969	23043
Mirtazapine	18377	17620
Prazosin	37639	35909
Tricyclics	7243	6991

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	116.69	115.74	-0.95334	(-0.954,-0.938)	0.1864	-0.82%	0.0718
Mirtazapine	117.4	116.89	-0.51172	(-0.513,-0.497)	0.5126	-0.44%	0.2531
Prazosin	116.29	115.09	-1.20747	(-1.208,-1.192)	0.0374	-1.04%	0.0013
Tricyclics	117.98	117.65	-0.33093	(-0.332,-0.316)	0.6904	-0.28%	0.0025

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	1805	1823
Mirtazapine	1580	1467
Prazosin	2886	2688
Tricyclics	1378	1303

Changes in LDL Cholesterol by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: male	0.81982	(0.332,1.307)	0.66248	(0.176,1.149)	1.04753	(0.487,1.608)
Antipsychotics: female	0.23933	(-1.569,2.048)	0.09233	(-1.709,1.894)	0.62228	(-1.336,2.58)
p-value for 3-way interaction	0.54357		0.54931		0.68236	
Mirtazapine: male	1.69318	(1.167,2.219)	1.63145	(1.106,2.156)	1.91397	(1.351,2.477)
Mirtazapine: female	0.68762	(-1.223,2.598)	0.73284	(-1.17,2.636)	1.08741	(-0.894,3.069)
p-value for 3-way interaction	0.31984		0.37229		0.43161	
Tricyclics: male	0.07186	(-0.673,0.816)	0.06123	(-0.682,0.805)	0.34333	(-0.221,0.908)
Tricyclics: female	0.8607	(-1.128,2.849)	0.838	(-1.143,2.819)	1.09618	(-0.88,3.072)
p-value for 3-way interaction	0.46654		0.47188		0.47273	
overall 3-way interaction p-value	0.46095		0.51098		0.46587	

**Changes in LDL Cholesterol by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	96.1051	93.6754	-2.42975	(-2.431,-2.415)	<.0001	-2.53%
Mirtazapine	94.875	93.7424	-1.13258	(-1.134,-1.118)	0.0077	-1.19%
Prazosin	97.0023	94.2643	-2.73796	(-2.739,-2.723)	<.0001	-2.82%
Tricyclics	95.9505	93.4219	-2.5286	(-2.53,-2.514)	0.0011	-2.64%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	4366	4205
Mirtazapine	4853	4606
Prazosin	8594	8368
Tricyclics	1428	1397

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	111.73	109.53	-2.19804	(-2.199,-2.183)	<.0001	-1.97%	0.6423
Mirtazapine	109.52	108.05	-1.47034	(-1.471,-1.455)	<.0001	-1.34%	0.4909
Prazosin	112.79	109.73	-3.05594	(-3.057,-3.041)	<.0001	-2.71%	0.3667
Tricyclics	110.85	108.18	-2.66753	(-2.669,-2.653)	<.0001	-2.41%	0.87

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	20408	20661
Mirtazapine	15104	14481
Prazosin	31931	30229
Tricyclics	7193	6897

Changes in LDL Cholesterol by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: &gt;=65</b>	0.29913	(-0.77,1.368)	0.19023	(-0.878,1.259)	0.40878	(-0.761,1.579)
<b>Antipsychotics: &lt;65</b>	0.84244	(0.318,1.367)	0.72958	(0.206,1.253)	1.13986	(0.534,1.746)
<b>p-value for 3-way interaction</b>	0.37121		0.37443		0.27678	
<b>Mirtazapine: &gt;=65</b>	1.60538	(0.573,2.638)	1.56982	(0.538,2.602)	1.58649	(0.416,2.757)
<b>Mirtazapine: &lt;65</b>	1.5838	(1.002,2.165)	1.56712	(0.986,2.148)	1.90908	(1.299,2.519)
<b>p-value for 3-way interaction</b>	0.97152		0.99644		0.6318	
<b>Tricyclics: &gt;=65</b>	0.20689	(-1.418,1.832)	0.31447	(-1.31,1.939)	0.3235	(-0.853,1.5)
<b>Tricyclics: &lt;65</b>	0.38353	(-0.382,1.149)	0.35277	(-0.412,1.117)	0.44575	(-0.165,1.057)
<b>p-value for 3-way interaction</b>	0.84716		0.96665		0.85654	
<b>overall 3-way interaction p-value</b>	0.81619		0.82233		0.71573	



**Changes in LDL Cholesterol by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	118.59	117.88	-0.7048	(-0.706,-0.69)	0.1679	-0.59%
Mirtazapine	116.56	117.44	0.87638	(0.875,0.891)	0.1581	0.75%
Prazosin	119.79	118.34	-1.44554	(-1.447,-1.431)	<.0001	-1.21%
Tricyclics	121.28	119.48	-1.79471	(-1.796,-1.78)	0.0537	-1.48%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	3831	3780
Mirtazapine	2686	2393
Prazosin	9586	8683
Tricyclics	1188	1059

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	107.16	104.74	-2.42643	(-2.427,-2.411)	<.0001	-2.26%	0.0018
Mirtazapine	104.28	102.65	-1.62789	(-1.629,-1.613)	<.0001	-1.56%	0.0002
Prazosin	106.08	102.74	-3.3436	(-3.345,-3.329)	<.0001	-3.15%	<.0001
Tricyclics	106.25	103.54	-2.71117	(-2.712,-2.696)	<.0001	-2.55%	0.3551

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	20943	21086
Mirtazapine	17271	16694
Prazosin	30939	29914
Tricyclics	7433	7235

Changes in LDL Cholesterol by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: OEF/OIF</b>	0.71567	(-0.463,1.894)	0.66959	(-0.505,1.844)	0.5317	(-0.803,1.866)
<b>Antipsychotics: other era</b>	0.90802	(0.393,1.423)	0.7784	(0.264,1.293)	1.14365	(0.555,1.732)
<b>p-value for 3-way interaction</b>	0.76944		0.86789		0.41085	
<b>Mirtazapine: OEF/OIF</b>	2.32833	(0.958,3.699)	2.29174	(0.926,3.657)	2.29249	(0.955,3.63)
<b>Mirtazapine: other era</b>	1.71853	(1.169,2.268)	1.68008	(1.131,2.229)	1.83558	(1.244,2.427)
<b>p-value for 3-way interaction</b>	0.41817		0.41524		0.54045	
<b>Tricyclics: OEF/OIF</b>	-0.35807	(-2.282,1.566)	-0.40329	(-2.321,1.514)	-1.48616	(-2.851,-0.122)
<b>Tricyclics: other era</b>	0.62915	(-0.115,1.374)	0.64655	(-0.097,1.39)	0.81687	(0.225,1.409)
<b>p-value for 3-way interaction</b>	0.34828		0.31705		0.00241	
<b>overall 3-way interaction p-value</b>	0.57547		0.56132		0.00244	

### Changes in Total Cholesterol by Augmenting Medication Group - Male vs. Female

#### Male

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	182.99	181.29	-1.69674	(-1.698,-1.682)	<.0001	-0.93%
Mirtazapine	178.89	178.93	0.04363	(0.043,0.059)	0.8688	0.02%
Prazosin	183.57	180.3	-3.27521	(-3.276,-3.26)	<.0001	-1.78%
Tricyclics	181.57	178.88	-2.69572	(-2.697,-2.681)	<.0001	-1.49%

#### Number of Windows - Male

Medications	n(pre)	n(post)
Antipsychotics	22917	23018
Mirtazapine	18317	17561
Prazosin	37442	35596
Tricyclics	7227	6992

#### Female

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	195.73	196.11	0.37552	(0.375,0.391)	0.6582	0.19%	0.0185
Mirtazapine	197.73	197.92	0.19553	(0.195,0.211)	0.8342	0.10%	0.8757
Prazosin	194.95	194.07	-0.87524	(-0.876,-0.86)	0.197	-0.45%	0.0006
Tricyclics	196.49	196.78	0.29347	(0.292,0.308)	0.7642	0.15%	0.0048

#### Number of Windows - Female

Medications	n(pre)	n(post)
Antipsychotics	1790	1818
Mirtazapine	1580	1466
Prazosin	2882	2689
Tricyclics	1364	1294

**Changes in Total Cholesterol by Augmenting Medication Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: male</b>	1.55957	(0.985,2.134)	1.39813	(0.825,1.972)	1.79686	(1.135,2.458)
<b>Antipsychotics: female</b>	1.23653	(-0.895,3.368)	1.10126	(-1.024,3.227)	1.31698	(-0.994,3.628)
<b>p-value for 3-way interaction</b>	0.77429		0.79156		0.6956	
<b>Mirtazapine: male</b>	3.30589	(2.686,3.926)	3.2232	(2.604,3.842)	3.59714	(2.933,4.262)
<b>Mirtazapine: female</b>	1.05233	(-1.194,3.298)	1.09813	(-1.142,3.338)	1.27674	(-1.056,3.609)
<b>p-value for 3-way interaction</b>	0.058		0.07306		0.06077	
<b>Tricyclics: male</b>	0.57342	(-0.303,1.45)	0.55197	(-0.324,1.428)	0.99444	(0.328,1.661)
<b>Tricyclics: female</b>	1.16039	(-1.183,3.504)	1.13227	(-1.205,3.47)	1.24605	(-1.084,3.576)
<b>p-value for 3-way interaction</b>	0.6457		0.64864		0.83874	
<b>overall 3-way interaction p-value</b>	0.17291		0.21194		0.1449	

## Changes in Total Cholesterol by Augmenting Medication Group - Age 65 and Over vs. Under 65

### Age >=65

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	168.42	166.09	-2.32453	(-2.326,-2.31)	<.0001	-1.38%
Mirtazapine	166.87	167.06	0.19389	(0.193,0.209)	0.704	0.12%
Prazosin	169.92	166.74	-3.1875	(-3.188,-3.172)	<.0001	-1.88%
Tricyclics	169.74	167.76	-1.97846	(-1.979,-1.963)	0.0302	-1.17%

### Number of Windows - Age >=65

Medications	n(pre)	n(post)
Antipsychotics	4326	4190
Mirtazapine	4826	4584
Prazosin	8493	8295
Tricyclics	1411	1381

### Age <65

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	187.13	185.7	-1.42973	(-1.431,-1.415)	<.0001	-0.76%	0.1271
Mirtazapine	184.65	184.63	-0.02135	(-0.022,-0.006)	0.9418	-0.01%	0.7145
Prazosin	188.14	185.1	-3.04666	(-3.048,-3.032)	<.0001	-1.62%	0.7339
Tricyclics	186.79	184.48	-2.30661	(-2.308,-2.292)	<.0001	-1.24%	0.7434

### Number of Windows - Age<65

Medications	n(pre)	n(post)
Antipsychotics	20381	20646
Mirtazapine	15071	14443
Prazosin	31831	29990
Tricyclics	7180	6905

**Changes in Total Cholesterol by Augmenting Medication Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: &gt;=65</b>	0.85652	(-0.407,2.12)	0.74934	(-0.514,2.013)	1.03771	(-0.348,2.424)
<b>Antipsychotics: &lt;65</b>	1.59612	(0.978,2.214)	1.49064	(0.873,2.108)	1.89784	(1.183,2.613)
<b>p-value for 3-way interaction</b>	0.30272		0.3015		0.2798	
<b>Mirtazapine: &gt;=65</b>	3.37813	(2.158,4.598)	3.33562	(2.115,4.556)	3.2845	(1.899,4.67)
<b>Mirtazapine: &lt;65</b>	3.01167	(2.327,3.697)	2.98528	(2.301,3.67)	3.41576	(2.696,4.135)
<b>p-value for 3-way interaction</b>	0.60773		0.62355		0.86912	
<b>Tricyclics: &gt;=65</b>	1.21971	(-0.707,3.146)	1.28897	(-0.638,3.216)	1.50014	(0.105,2.895)
<b>Tricyclics: &lt;65</b>	0.7388	(-0.162,1.639)	0.71088	(-0.189,1.611)	0.89567	(0.175,1.617)
<b>p-value for 3-way interaction</b>	0.65757		0.59414		0.45059	
<b>overall 3-way interaction p-value</b>	0.52535		0.50979		0.3373	

**Changes in Total Cholesterol by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	192.67	193.73	1.06275	(1.062,1.078)	0.0745	0.55%
Mirtazapine	190.79	194.2	3.41227	(3.411,3.427)	<.0001	1.79%
Prazosin	194.62	193.8	-0.82134	(-0.822,-0.806)	0.0299	-0.42%
Tricyclics	196.8	195.55	-1.24633	(-1.247,-1.231)	0.2545	-0.63%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	3866	3799
Mirtazapine	2682	2385
Prazosin	9639	8695
Tricyclics	1185	1060

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	182.18	180.22	-1.95534	(-1.956,-1.94)	<.0001	-1.07%	<.0001
Mirtazapine	178.68	178.32	-0.3558	(-0.357,-0.341)	0.1881	-0.20%	<.0001
Prazosin	180.91	177.27	-3.64911	(-3.65,-3.634)	<.0001	-2.02%	<.0001
Tricyclics	181.87	179.52	-2.34291	(-2.344,-2.328)	<.0001	-1.29%	0.3468

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	20841	21037
Mirtazapine	17215	16642
Prazosin	30685	29590
Tricyclics	7406	7226

Changes in Total Cholesterol by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: OEF/OIF</b>	1.84762	(0.467,3.228)	1.82181	(0.445,3.198)	1.60661	(0.039,3.174)
<b>Antipsychotics: other era</b>	1.68354	(1.076,2.292)	1.54	(0.933,2.147)	1.86631	(1.17,2.563)
<b>p-value for 3-way interaction</b>	0.8312		0.71352		0.76664	
<b>Mirtazapine: OEF/OIF</b>	4.21491	(2.603,5.827)	4.16864	(2.561,5.776)	4.18146	(2.606,5.757)
<b>Mirtazapine: other era</b>	3.28835	(2.64,3.936)	3.23114	(2.584,3.879)	3.37458	(2.675,4.074)
<b>p-value for 3-way interaction</b>	0.296		0.28898		0.35885	
<b>Tricyclics: OEF/OIF</b>	-0.42538	(-2.692,1.841)	-0.48108	(-2.74,1.778)	-1.45967	(-3.069,0.15)
<b>Tricyclics: other era</b>	1.30871	(0.431,2.186)	1.31692	(0.44,2.194)	1.5689	(0.869,2.269)
<b>p-value for 3-way interaction</b>	0.16193		0.1459		0.00072	
<b>overall 3-way interaction p-value</b>	0.2973		0.26156		0.00021	



### Changes in Systolic Blood Pressure by Augmenting Medication Group - Male vs. Female

#### Male

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	130.05	129.26	-0.79626	(-0.797,-0.781)	<.0001	-0.61%
Mirtazapine	129.8	130.05	0.25295	(0.252,0.268)	0.0005	0.20%
Prazosin	131.25	130.37	-0.87662	(-0.878,-0.862)	<.0001	-0.67%
Tricyclics	130.19	130.02	-0.17078	(-0.172,-0.156)	0.1045	-0.13%

#### Number of Windows - Male

Medications	n(pre)	n(post)
Antipsychotics	28387	28080
Mirtazapine	22113	21843
Prazosin	46254	45365
Tricyclics	8650	8547

#### Female

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	123.69	123.7	0.00796	(0.007,0.023)	0.9712	0.01%	0.0005
Mirtazapine	123.73	124.65	0.91459	(0.914,0.93)	<.0001	0.74%	0.007
Prazosin	124.69	124.11	-0.58028	(-0.581,-0.565)	0.0005	-0.47%	0.0878
Tricyclics	123.88	124.32	0.43922	(0.438,0.454)	0.0545	0.36%	0.0153

#### Number of Windows - Female

Medications	n(pre)	n(post)
Antipsychotics	2434	2429
Mirtazapine	2090	2071
Prazosin	4069	4006
Tricyclics	1831	1815

**Changes in Systolic Blood Pressure by Augmenting Medication Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: male</b>	0.08052	(-0.077,0.238)	0.09012	(-0.067,0.248)	0.23489	(0.056,0.414)
<b>Antipsychotics: female</b>	0.58787	(0.054,1.122)	0.59199	(0.058,1.126)	0.55243	(-0.018,1.123)
<b>p-value for 3-way interaction</b>	0.07396		0.07707		0.29791	
<b>Mirtazapine: male</b>	1.13004	(0.959,1.301)	1.13611	(0.966,1.307)	1.23678	(1.058,1.416)
<b>Mirtazapine: female</b>	1.49646	(0.936,2.057)	1.50154	(0.941,2.062)	1.5201	(0.951,2.09)
<b>p-value for 3-way interaction</b>	0.22058		0.22175		0.35225	
<b>Tricyclics: male</b>	0.70765	(0.464,0.951)	0.71652	(0.473,0.96)	0.81976	(0.64,1)
<b>Tricyclics: female</b>	1.01825	(0.433,1.604)	1.01628	(0.431,1.602)	1.16995	(0.601,1.739)
<b>p-value for 3-way interaction</b>	0.33706		0.35412		0.25009	
<b>overall 3-way interaction p-value</b>	0.30169		0.31128		0.64411	

**Changes in Systolic Blood Pressure by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	130.87	129.72	-1.15351	(-1.154,-1.139)	<.0001	-0.88%
Mirtazapine	131.16	131.2	0.04168	(0.041,0.057)	0.77	0.03%
Prazosin	133.17	132.35	-0.81623	(-0.817,-0.801)	<.0001	-0.61%
Tricyclics	131.82	131.58	-0.24716	(-0.248,-0.232)	0.3092	-0.19%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	5145	5031
Mirtazapine	5628	5576
Prazosin	9809	9725
Tricyclics	1621	1594

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	129.29	128.64	-0.64902	(-0.65,-0.634)	<.0001	-0.50%	0.0025
Mirtazapine	128.71	129.1	0.39091	(0.39,0.406)	<.0001	0.30%	0.0321
Prazosin	130.13	129.27	-0.8659	(-0.867,-0.851)	<.0001	-0.67%	0.6763
Tricyclics	128.59	128.56	-0.03089	(-0.032,-0.016)	0.7664	-0.02%	0.4133

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	5145	5031
Mirtazapine	5628	5576
Prazosin	9809	9725
Tricyclics	1621	1594

Changes in Systolic Blood Pressure by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: &gt;=65</b>	-0.33729	(-0.696,0.022)	-0.32969	(-0.688,0.029)	-0.00058	(-0.391,0.39)
<b>Antipsychotics: &lt;65</b>	0.21711	(0.05,0.384)	0.22433	(0.058,0.391)	0.32773	(0.138,0.518)
<b>p-value for 3-way interaction</b>	0.00603		0.00605		0.13833	
<b>Mirtazapine: &gt;=65</b>	0.8574	(0.51,1.205)	0.86067	(0.513,1.208)	1.04826	(0.659,1.437)
<b>Mirtazapine: &lt;65</b>	1.25763	(1.073,1.443)	1.26312	(1.078,1.448)	1.3153	(1.125,1.506)
<b>p-value for 3-way interaction</b>	0.04623		0.04501		0.22686	
<b>Tricyclics: &gt;=65</b>	0.56983	(0.013,1.127)	0.57067	(0.014,1.128)	0.78593	(0.392,1.18)
<b>Tricyclics: &lt;65</b>	0.83655	(0.592,1.081)	0.84565	(0.602,1.09)	0.87094	(0.681,1.061)
<b>p-value for 3-way interaction</b>	0.3901		0.37554		0.70348	
<b>overall 3-way interaction p-value</b>	0.03288		0.03253		0.41198	

## Changes in Systolic Blood Pressure by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

### Iraq and Afghanistan Era

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	126.86	126.58	-0.27452	(-0.276,-0.26)	0.0651	-0.22%
Mirtazapine	126.19	126.58	0.39872	(0.398,0.414)	0.0252	0.32%
Prazosin	127.73	127.26	-0.4772	(-0.478,-0.462)	<.0001	-0.37%
Tricyclics	125.9	126.31	0.4031	(0.402,0.418)	0.0944	0.32%

### Number of Windows - Iraq and Afghanistan Era

Medications	n(pre)	n(post)
Antipsychotics	5503	5383
Mirtazapine	3751	3617
Prazosin	13740	13219
Tricyclics	1670	1640

### Other Era

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	130.14	129.31	-0.83404	(-0.835,-0.819)	<.0001	-0.64%	0.0006
Mirtazapine	129.85	130.14	0.28805	(0.287,0.303)	0.0001	0.22%	0.5669
Prazosin	131.86	130.85	-1.0004	(-1.001,-0.985)	<.0001	-0.76%	<.0001
Tricyclics	129.7	129.54	-0.15405	(-0.155,-0.139)	0.1389	-0.12%	0.0338

### Number of Windows - Other Era

Medications	n(pre)	n(post)
Antipsychotics	25318	25126
Mirtazapine	20452	20297
Prazosin	36583	36152
Tricyclics	8811	8722

**Changes in Systolic Blood Pressure by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: OEF/OIF</b>	0.20257	(-0.135,0.54)	0.20768	(-0.129,0.545)	0.22082	(-0.156,0.597)
<b>Antipsychotics: other era</b>	0.16656	(-0.004,0.337)	0.17312	(0.003,0.343)	0.30519	(0.113,0.497)
<b>p-value for 3-way interaction</b>	0.85174		0.85763		0.69572	
<b>Mirtazapine: OEF/OIF</b>	0.87526	(0.485,1.265)	0.88065	(0.491,1.271)	0.89289	(0.519,1.267)
<b>Mirtazapine: other era</b>	1.28893	(1.107,1.47)	1.29336	(1.112,1.475)	1.37673	(1.184,1.569)
<b>p-value for 3-way interaction</b>	0.05956		0.06011		0.02411	
<b>Tricyclics: OEF/OIF</b>	0.88088	(0.338,1.424)	0.88516	(0.343,1.428)	0.9839	(0.607,1.361)
<b>Tricyclics: other era</b>	0.84746	(0.601,1.094)	0.8512	(0.605,1.098)	0.85625	(0.663,1.049)
<b>p-value for 3-way interaction</b>	0.91249		0.91106		0.5544	
<b>overall 3-way interaction p-value</b>	0.24099		0.24367		0.03529	

**Changes in Diastolic Blood Pressure by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	78.0341	77.7291	-0.30499	(-0.306,-0.29)	<.0001	-0.39%
Mirtazapine	77.5111	77.6161	0.10504	(0.104,0.12)	0.0261	0.14%
Prazosin	79.1228	78.4016	-0.72115	(-0.722,-0.706)	<.0001	-0.91%
Tricyclics	77.7666	77.9848	0.21825	(0.217,0.233)	0.0021	0.28%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	28387	28080
Mirtazapine	22113	21843
Prazosin	46254	45365
Tricyclics	8650	8547

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	76.1762	76.4796	0.30339	(0.302,0.318)	0.0384	0.40%	<.0001
Mirtazapine	75.884	76.2364	0.35242	(0.351,0.367)	0.0216	0.46%	0.1233
Prazosin	76.8958	76.6372	-0.25853	(-0.26,-0.244)	0.0219	-0.34%	<.0001
Tricyclics	75.9726	76.6755	0.70285	(0.702,0.718)	<.0001	0.93%	0.0043

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	2434	2429
Mirtazapine	2090	2071
Prazosin	4069	4006
Tricyclics	1831	1815

**Changes in Diastolic Blood Pressure by Augmenting Medication Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: male</b>	0.41612	(0.311,0.521)	0.40711	(0.302,0.512)	0.4637	(0.343,0.584)
<b>Antipsychotics: female</b>	0.56192	(0.205,0.919)	0.56222	(0.205,0.919)	0.55892	(0.175,0.943)
<b>p-value for 3-way interaction</b>	0.44266		0.41413		0.64255	
<b>Mirtazapine: male</b>	0.82614	(0.712,0.94)	0.82174	(0.708,0.936)	0.91679	(0.796,1.037)
<b>Mirtazapine: female</b>	0.61226	(0.237,0.987)	0.61848	(0.243,0.994)	0.70952	(0.327,1.092)
<b>p-value for 3-way interaction</b>	0.28504		0.30973		0.31158	
<b>Tricyclics: male</b>	0.9399	(0.777,1.103)	0.93021	(0.767,1.093)	1.06107	(0.94,1.182)
<b>Tricyclics: female</b>	0.9609	(0.569,1.352)	0.95722	(0.566,1.349)	1.05556	(0.673,1.438)
<b>p-value for 3-way interaction</b>	0.92267		0.90069		0.97852	
<b>overall 3-way interaction p-value</b>	0.4423		0.44749		0.50734	



**Changes in Diastolic Blood Pressure by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	73.7365	73.0854	-0.65105	(-0.652,-0.636)	<.0001	-0.88%
Mirtazapine	73.7678	73.669	-0.09877	(-0.1,-0.084)	0.2893	-0.13%
Prazosin	75.9979	75.1018	-0.89613	(-0.897,-0.881)	<.0001	-1.18%
Tricyclics	74.5153	74.6383	0.12299	(0.122,0.138)	0.4538	0.17%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	5145	5031
Mirtazapine	5628	5576
Prazosin	9809	9725
Tricyclics	1621	1594

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	78.7095	78.528	-0.1816	(-0.183,-0.167)	<.0001	-0.23%	<.0001
Mirtazapine	78.4538	78.6501	0.19636	(0.195,0.211)	0.0001	0.25%	0.0056
Prazosin	79.6501	79.0223	-0.62781	(-0.629,-0.613)	<.0001	-0.79%	0.0009
Tricyclics	77.9876	78.3222	0.3346	(0.334,0.35)	<.0001	0.43%	0.236

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	25676	25478
Mirtazapine	18575	18338
Prazosin	40514	39646
Tricyclics	8860	8768

**Changes in Diastolic Blood Pressure by Augmenting Medication Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: &gt;=65</b>	0.24483	(0.005,0.485)	0.24203	(0.002,0.482)	0.31619	(0.054,0.579)
<b>Antipsychotics: &lt;65</b>	0.44604	(0.335,0.558)	0.44362	(0.332,0.555)	0.50362	(0.376,0.632)
<b>p-value for 3-way interaction</b>	0.13611		0.1354		0.20825	
<b>Mirtazapine: &gt;=65</b>	0.79693	(0.565,1.029)	0.79606	(0.564,1.028)	0.80791	(0.546,1.069)
<b>Mirtazapine: &lt;65</b>	0.82441	(0.701,0.948)	0.82443	(0.701,0.948)	0.91855	(0.791,1.047)
<b>p-value for 3-way interaction</b>	0.83781		0.8327		0.45646	
<b>Tricyclics: &gt;=65</b>	1.0194	(0.647,1.392)	1.01713	(0.644,1.39)	1.14	(0.875,1.405)
<b>Tricyclics: &lt;65</b>	0.96271	(0.799,1.126)	0.95895	(0.796,1.122)	1.0373	(0.909,1.165)
<b>p-value for 3-way interaction</b>	0.78472		0.77922		0.49404	
<b>overall 3-way interaction p-value</b>	0.44403		0.44155		0.23174	

**Changes in Diastolic Blood Pressure by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	78.6839	79.0645	0.38061	(0.38,0.396)	0.0001	0.48%
Mirtazapine	78.7143	79.2829	0.56868	(0.568,0.584)	<.0001	0.72%
Prazosin	79.6945	79.5158	-0.17875	(-0.18,-0.164)	0.0041	-0.22%
Tricyclics	78.3837	79.1679	0.78422	(0.783,0.799)	<.0001	1.00%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	5503	5383
Mirtazapine	3751	3617
Prazosin	13740	13219
Tricyclics	1670	1640

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	77.7089	77.3186	-0.39025	(-0.391,-0.375)	<.0001	-0.50%	<.0001
Mirtazapine	77.1189	77.1699	0.05105	(0.05,0.066)	0.2968	0.07%	<.0001
Prazosin	78.6533	77.7903	-0.86301	(-0.864,-0.848)	<.0001	-1.10%	<.0001
Tricyclics	77.2742	77.4878	0.21362	(0.213,0.229)	0.0024	0.28%	0.0013

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	25318	25126
Mirtazapine	20452	20297
Prazosin	36583	36152
Tricyclics	8811	8722

**Changes in Diastolic Blood Pressure by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: OEF/OIF</b>	0.5595	(0.334,0.785)	0.55757	(0.332,0.783)	0.55089	(0.298,0.804)
<b>Antipsychotics: other era</b>	0.47264	(0.359,0.586)	0.46577	(0.352,0.58)	0.48746	(0.358,0.617)
<b>p-value for 3-way interaction</b>	0.50035		0.47619		0.66196	
<b>Mirtazapine: OEF/OIF</b>	0.74748	(0.486,1.009)	0.74842	(0.487,1.009)	0.79166	(0.54,1.043)
<b>Mirtazapine: other era</b>	0.91415	(0.793,1.035)	0.91143	(0.79,1.033)	0.95431	(0.825,1.084)
<b>p-value for 3-way interaction</b>	0.25649		0.26703		0.25957	
<b>Tricyclics: OEF/OIF</b>	0.96393	(0.601,1.327)	0.95299	(0.59,1.316)	1.02851	(0.775,1.282)
<b>Tricyclics: other era</b>	1.07677	(0.912,1.241)	1.07265	(0.908,1.237)	1.0994	(0.97,1.229)
<b>p-value for 3-way interaction</b>	0.57889		0.55619		0.62539	
<b>overall 3-way interaction p-value</b>	0.45361		0.44291		0.46377	

**Differences in Incident Diagnoses of Diabetes (Per 100 Person Years) by Augmenting Mediation Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: male	1.41275	(1.08,1.74)	1.08659	(0.79,1.39)	0.72111	(0.33,1.11)
Antipsychotics: female	0.0525	(-0.71,0.82)	-0.03225	(-0.93,0.86)	-0.17355	(-1.02,0.67)
p-value for 2-way interaction	0.07827		0.09055		0.20178	
Mirtazapine: male	0.88183	(0.53,1.23)	0.38504	(0.07,0.7)	0.32212	(-0.06,0.7)
Mirtazapine: female	-0.09758	(-0.9,0.7)	-0.33564	(-1.25,0.58)	-0.45831	(-1.27,0.35)
p-value for 2-way interaction	0.16631		0.20154		0.14077	
Tricyclics: male	1.59151	(1.05,2.13)	1.30397	(0.82,1.79)	0.83599	(0.43,1.24)
Tricyclics: female	0.52239	(-0.35,1.4)	0.39618	(-0.61,1.4)	0.03778	(-0.82,0.9)
p-value for 2-way interaction	0.40048		0.2999		0.34049	
overall 2-way interaction p-value	0.28772		0.32256		0.45652	

**Number of Windows**

Medications	male	female
Antipsychotics	22297	2251
Mirtazapine	16553	1883
Prazosin	35607	3781
Tricyclics	5619	1635

**Differences in Incident Diagnoses of Diabetes (Per 100 Person Years) by Augmenting Mediation Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: >=65	1.45021	(0.53,2.38)	0.17606	(-0.18,0.53)	1.21056	(0.17,2.26)
Antipsychotics: <65	1.29484	(0.97,1.62)	1.01714	(0.68,1.35)	0.53199	(0.15,0.92)
p-value for 2-way interaction	0.69035		0.11762		0.35359	
Mirtazapine: >=65	0.751	(-0.12,1.63)	0.032	(-0.31,0.38)	0.7947	(-0.22,1.81)
Mirtazapine: <65	0.72792	(0.38,1.08)	0.3166	(-0.04,0.67)	0.14081	(-0.23,0.52)
p-value for 2-way interaction	0.71563		0.52139		0.2796	
Tricyclics: >=65	1.32768	(-0.18,2.84)	0.42467	(-0.19,1.04)	1.08439	(0.03,2.14)
Tricyclics: <65	1.20003	(0.71,1.69)	1.02827	(0.52,1.53)	0.68183	(0.29,1.08)
p-value for 2-way interaction	0.80339		0.77894		0.66622	
overall 2-way interaction p-value	0.9742		0.48138		0.69468	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	3175	21373
Mirtazapine	3477	14959
Prazosin	5885	33503
Tricyclics	820	6434

**Differences in Incident Diagnoses of Diabetes (Per 100 Person Years) by Augmenting Mediation Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: OEF/OIF	0.06471	(-0.32,0.45)	0.21702	(-0.34,0.77)	-0.02647	(-0.47,0.42)
Antipsychotics: other era	1.21814	(0.81,1.62)	1.1279	(0.78,1.47)	0.61674	(0.15,1.09)
p-value for 2-way interaction	0.1041		0.16558		0.32724	
Mirtazapine: OEF/OIF	-0.50048	(-0.93,-0.07)	-0.67609	(-1.29,-0.07)	-0.59669	(-1,-0.19)
Mirtazapine: other era	0.59409	(0.17,1.02)	0.46031	(0.1,0.82)	0.32076	(-0.14,0.78)
p-value for 2-way interaction	0.00339		0.00549		0.00153	
Tricyclics: OEF/OIF	0.16992	(-0.47,0.81)	0.1818	(-0.7,1.06)	-0.0346	(-0.48,0.41)
Tricyclics: other era	1.01013	(0.41,1.61)	1.13941	(0.61,1.67)	0.80205	(0.32,1.29)
p-value for 2-way interaction	0.59631		0.34136		0.21375	
overall 2-way interaction p-value	0.02322		0.03749		0.0171	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	5621	18927
Mirtazapine	3796	14640
Prazosin	13769	25619
Tricyclics	1624	5630

**Differences in Incident Diagnoses of Dyslipidemia (Per 100 Person Years) by Augmenting Mediation Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: male	6.27209	(5.43,7.11)	4.57626	(3.35,5.8)	3.93274	(2.93,4.94)
Antipsychotics: female	4.67938	(2.9,6.46)	4.84124	(1.7,7.99)	3.65722	(1.65,5.66)
p-value for 2-way interaction	0.34662		0.39411		0.23477	
Mirtazapine: male	3.10218	(2.18,4.03)	1.59049	(0.27,2.91)	1.48809	(0.5,2.47)
Mirtazapine: female	2.75432	(0.91,4.6)	2.42327	(-0.79,5.63)	1.46435	(-0.44,3.36)
p-value for 2-way interaction	0.35657		0.46426		0.55385	
Tricyclics: male	5.8832	(4.5,7.26)	4.26222	(2.27,6.26)	2.8543	(1.84,3.87)
Tricyclics: female	1.62603	(-0.26,3.51)	1.28106	(-2.01,4.57)	-0.0072	(-1.84,1.83)
p-value for 2-way interaction	0.14735		0.41005		0.12445	
overall 2-way interaction p-value	0.12725		0.43654		0.0349	

**Number of Windows**

Medications	male	female
Antipsychotics	12858	1632
Mirtazapine	8512	1266
Prazosin	19501	2808
Tricyclics	3074	1105

**Differences in Incident Diagnoses of Dyslipidemia (Per 100 Person Years) by Augmenting Mediation Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: >=65	6.27209	(5.43,7.11)	4.57626	(3.35,5.8)	3.93274	(2.93,4.94)
Antipsychotics: <65	4.67938	(2.9,6.46)	4.84124	(1.7,7.99)	3.65722	(1.65,5.66)
p-value for 2-way interaction	0.34662		0.39411		0.23477	
Mirtazapine: >=65	3.10218	(2.18,4.03)	1.59049	(0.27,2.91)	1.48809	(0.5,2.47)
Mirtazapine: <65	2.75432	(0.91,4.6)	2.42327	(-0.79,5.63)	1.46435	(-0.44,3.36)
p-value for 2-way interaction	0.35657		0.46426		0.55385	
Tricyclics: >=65	5.8832	(4.5,7.26)	4.26222	(2.27,6.26)	2.8543	(1.84,3.87)
Tricyclics: <65	1.62603	(-0.26,3.51)	1.28106	(-2.01,4.57)	-0.0072	(-1.84,1.83)
p-value for 2-way interaction	0.14735		0.41005		0.12445	
overall 2-way interaction p-value	0.12725		0.43654		0.0349	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	1416	13074
Mirtazapine	1347	8431
Prazosin	2278	20031
Tricyclics	341	3838

**Differences in Incident Diagnoses of Dyslipidemia (Per 100 Person Years) by Augmenting Mediation Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: OEF/OIF	1.92305	(0.81,3.03)	2.5319	(-0.23,5.29)	1.95378	(0.67,3.24)
Antipsychotics: other era	6.33897	(5.31,7.37)	5.13699	(3.21,7.06)	4.02148	(2.81,5.23)
p-value for 2-way interaction	0.00449		0.32479		0.54055	
Mirtazapine: OEF/OIF	-0.02781	(-1.29,1.23)	0.15895	(-2.96,3.27)	-0.22417	(-1.45,1)
Mirtazapine: other era	2.63246	(1.52,3.74)	2.04684	(0.01,4.09)	1.7539	(0.56,2.95)
p-value for 2-way interaction	0.03031		0.41198		0.08607	
Tricyclics: OEF/OIF	0.21141	(-1.62,2.04)	0.23988	(-4.24,4.72)	0.47322	(-0.8,1.74)
Tricyclics: other era	3.46045	(1.96,4.96)	3.6449	(0.81,6.48)	2.63835	(1.42,3.85)
p-value for 2-way interaction	0.08159		0.31621		0.15438	
overall 2-way interaction p-value	0.01221		0.60964		0.29317	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	4056	10434
Mirtazapine	2677	7101
Prazosin	9603	12706
Tricyclics	1112	3067

**Differences in Incident Diagnoses of Hypertension (Per 100 Person Years) by Augmenting Mediation Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: male	5.73776	(5,6.48)	3.60333	(2.97,4.24)	2.86287	(1.98,3.75)
Antipsychotics: female	1.96014	(0.56,3.36)	1.80132	(0.2,3.41)	1.03086	(-0.52,2.58)
p-value for 2-way interaction	0.24003		0.46188		0.6567	
Mirtazapine: male	4.30502	(3.49,5.12)	1.97747	(1.3,2.66)	1.99191	(1.12,2.87)
Mirtazapine: female	0.76222	(-0.67,2.2)	0.15537	(-1.45,1.76)	-0.05429	(-1.53,1.42)
p-value for 2-way interaction	0.09679		0.18962		0.21362	
Tricyclics: male	4.91545	(3.73,6.1)	2.87167	(1.86,3.88)	1.80247	(0.92,2.68)
Tricyclics: female	2.88382	(1.29,4.47)	2.77525	(0.96,4.59)	1.77252	(0.17,3.37)
p-value for 2-way interaction	0.7801		0.5019		0.33828	
overall 2-way interaction p-value	0.2205		0.30847		0.13615	

**Number of Windows**

Medications	male	female
Antipsychotics	12714	1681
Mirtazapine	8661	1371
Prazosin	20267	2900
Tricyclics	3145	1205

**Differences in Incident Diagnoses of Hypertension (Per 100 Person Years) by Augmenting Mediation Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: >=65	9.06178	(6.19,11.93)	2.09184	(1.05,3.13)	4.72678	(1.46,7.99)
Antipsychotics: <65	5.06084	(4.38,5.75)	3.15325	(2.5,3.8)	2.40224	(1.59,3.21)
p-value for 2-way interaction	0.52813		0.79865		0.5896	
Mirtazapine: >=65	3.24633	(0.49,6)	0.50853	(-0.47,1.48)	1.69456	(-1.5,4.88)
Mirtazapine: <65	3.62221	(2.87,4.37)	1.7788	(1.07,2.48)	1.71085	(0.91,2.51)
p-value for 2-way interaction	0.14407		0.33312		0.60583	
Tricyclics: >=65	7.91263	(3.23,12.59)	2.44673	(0.69,4.21)	5.71915	(2.32,9.12)
Tricyclics: <65	3.38535	(2.39,4.38)	2.08114	(1.13,3.04)	1.42802	(0.62,2.23)
p-value for 2-way interaction	0.36531		0.26073		0.07087	
overall 2-way interaction p-value	0.15974		0.36894		0.09252	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	1163	13232
Mirtazapine	1130	8902
Prazosin	2013	21154
Tricyclics	288	4062



**Differences in Incident Diagnoses of Hypertension (Per 100 Person Years) by Augmenting Mediation Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: OEF/OIF	0.57525	(-0.24,1.39)	1.20813	(0.09,2.32)	0.43197	(-0.51,1.37)
Antipsychotics: other era	5.7294	(4.77,6.69)	3.99389	(3.27,4.72)	2.73085	(1.6,3.86)
p-value for 2-way interaction	0.00012		0.00376		0.18437	
Mirtazapine: OEF/OIF	0.02972	(-0.9,0.96)	0.22433	(-1.04,1.49)	-0.27222	(-1.18,0.64)
Mirtazapine: other era	3.50708	(2.48,4.54)	2.15365	(1.4,2.91)	1.89365	(0.78,3.01)
p-value for 2-way interaction	0.00647		0.04209		0.04486	
Tricyclics: OEF/OIF	-0.71597	(-2.04,0.6)	-1.11739	(-2.86,0.63)	-1.02476	(-1.92,-0.13)
Tricyclics: other era	3.50814	(2.14,4.88)	3.39231	(2.33,4.46)	2.34685	(1.21,3.48)
p-value for 2-way interaction	0.00421		0.0004		0.00017	
overall 2-way interaction p-value	0.00009		0.00038		0.00218	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	4401	9994
Mirtazapine	2952	7080
Prazosin	10684	12483
Tricyclics	1280	3070

**Differences in Incident Diagnoses of Obesity (Per 100 Person Years) by Augmenting Mediation Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: male	0.36414	(-0.12,0.85)	0.52659	(0.04,1.01)	0.2122	(-0.36,0.78)
Antipsychotics: female	-0.25592	(-2.21,1.7)	0.00236	(-1.84,1.85)	-0.87546	(-3.02,1.27)
p-value for 2-way interaction	0.49024		0.51666		0.3208	
Mirtazapine: male	-0.6816	(-1.2,-0.16)	-0.50258	(-1.02,0.02)	-0.41718	(-0.97,0.14)
Mirtazapine: female	-0.99734	(-3,1.01)	-0.64866	(-2.55,1.25)	-1.32906	(-3.42,0.76)
p-value for 2-way interaction	0.92613		0.98594		0.48572	
Tricyclics: male	0.18947	(-0.59,0.97)	0.19683	(-0.57,0.96)	-0.37924	(-0.95,0.19)
Tricyclics: female	0.92848	(-1.31,3.17)	0.93575	(-1.17,3.04)	0.98654	(-1.26,3.23)
p-value for 2-way interaction	0.59395		0.56388		0.2105	
overall 2-way interaction p-value	0.76851		0.76844		0.10351	

**Number of Windows**

Medications	male	female
Antipsychotics	22128	1720
Mirtazapine	17074	1535
Prazosin	32413	2688
Tricyclics	6043	1181

**Differences in Incident Diagnoses of Obesity (Per 100 Person Years) by Augmenting Mediation Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: >=65	-0.97222	(-1.94,0)	-1.00848	(-1.9,-0.11)	-0.13796	(-1.23,0.95)
Antipsychotics: <65	0.48316	(-0.05,1.02)	0.57031	(0.02,1.12)	0.16963	(-0.46,0.8)
p-value for 2-way interaction	0.01399		0.00536		0.67147	
Mirtazapine: >=65	-1.1598	(-2.1,-0.22)	-1.16678	(-2.04,-0.3)	-0.65316	(-1.72,0.41)
Mirtazapine: <65	-0.40375	(-0.99,0.18)	-0.40992	(-1.01,0.19)	-0.45736	(-1.07,0.16)
p-value for 2-way interaction	0.08967		0.05824		0.55439	
Tricyclics: >=65	0.55267	(-1.09,2.19)	0.41635	(-1.1,1.93)	0.33214	(-0.81,1.47)
Tricyclics: <65	0.46352	(-0.35,1.27)	0.24129	(-0.58,1.06)	-0.43389	(-1.06,0.19)
p-value for 2-way interaction	0.81461		0.76074		0.30202	
overall 2-way interaction p-value	0.05008		0.01823		0.36011	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	3919	19929
Mirtazapine	4230	14379
Prazosin	6544	28557
Tricyclics	1056	6168

**Differences in Incident Diagnoses of Obesity (Per 100 Person Years) by Augmenting Mediation Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: OEF/OIF	-0.81203	(-1.78,0.15)	-0.66212	(-1.48,0.16)	-0.78775	(-1.88,0.31)
Antipsychotics: other era	0.51869	(-0.03,1.07)	0.68507	(0.12,1.25)	0.32707	(-0.31,0.97)
p-value for 2-way interaction	0.02077		0.01291		0.08695	
Mirtazapine: OEF/OIF	-0.89977	(-2.01,0.21)	-0.6832	(-1.63,0.27)	-0.73732	(-1.82,0.34)
Mirtazapine: other era	-0.70649	(-1.28,-0.13)	-0.49623	(-1.09,0.1)	-0.44496	(-1.07,0.18)
p-value for 2-way interaction	0.71808		0.58629		0.61104	
Tricyclics: OEF/OIF	-0.51062	(-2.12,1.1)	-0.54973	(-1.91,0.81)	-1.85386	(-2.93,-0.78)
Tricyclics: other era	0.7759	(-0.05,1.6)	0.61091	(-0.23,1.45)	0.1456	(-0.5,0.79)
p-value for 2-way interaction	0.18137		0.1875		0.00138	
overall 2-way interaction p-value	0.09708		0.07302		0.00799	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	4581	19267
Mirtazapine	3152	15457
Prazosin	10760	24341
Tricyclics	1313	5911

**Comparison of New Prescription or Dose Increase of a Diabetes Medication by Augmenting Medication Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: male	0.80401	(0.37,1.24)	0.15163	(-0.23,0.54)	0.34197	(-0.17,0.86)
Antipsychotics: female	0.48582	(-0.6,1.57)	0.32361	(-1.02,1.67)	-0.24136	(-1.47,0.99)
p-value for 2-way interaction	0.92438		0.76851		0.50247	
Mirtazapine: male	1.40292	(0.93,1.88)	-0.35257	(-0.76,0.05)	0.02328	(-0.49,0.54)
Mirtazapine: female	1.20003	(0.03,2.37)	0.35905	(-1.01,1.73)	-0.32172	(-1.54,0.9)
p-value for 2-way interaction	0.49228		0.37189		0.60107	
Tricyclics: male	5.09868	(4.4,5.8)	2.49564	(1.9,3.09)	1.70784	(1.17,2.24)
Tricyclics: female	2.23095	(0.97,3.49)	1.82391	(0.33,3.32)	0.64842	(-0.63,1.92)
p-value for 2-way interaction	0.49496		0.91751		0.62965	
overall 2-way interaction p-value	0.67916		0.79513		0.91695	

**Number of Windows**

Medications	male	female
Antipsychotics	29413	2516
Mirtazapine	22750	2157
Prazosin	48061	4228
Tricyclics	8777	1860

**Comparison of New Prescription or Dose Increase of a Diabetes Medication by Augmenting Medication Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: >=65	0.88854	(-0.24,2.02)	-0.94988	(-1.45,-0.45)	1.37713	(0.11,2.65)
Antipsychotics: <65	0.91561	(0.48,1.35)	0.32326	(-0.13,0.78)	0.04704	(-0.47,0.56)
p-value for 2-way interaction	0.53452		0.00007		0.07837	
Mirtazapine: >=65	0.21709	(-0.87,1.31)	-1.18161	(-1.66,-0.7)	0.19693	(-1.05,1.44)
Mirtazapine: <65	1.48682	(1,1.97)	0.05276	(-0.44,0.54)	-0.05655	(-0.57,0.46)
p-value for 2-way interaction	0.00591		0.00002		0.70669	
Tricyclics: >=65	3.95484	(2.17,5.74)	0.60184	(-0.21,1.41)	0.91071	(-0.36,2.18)
Tricyclics: <65	4.37975	(3.71,5.04)	2.34302	(1.69,3)	1.78426	(1.25,2.32)
p-value for 2-way interaction	0.06364		0.06641		0.06312	
overall 2-way interaction p-value	0.02439		0.00001		0.00348	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	5253	26676
Mirtazapine	5721	19186
Prazosin	10066	42223
Tricyclics	1634	9003

**Comparison of New Prescription or Dose Increase of a Diabetes Medication by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: OEF/OIF	-0.63141	(-1.14,-0.12)	-0.82336	(-1.58,-0.06)	-0.72969	(-1.31,-0.15)
Antipsychotics: other era	0.08625	(-0.42,0.6)	0.08098	(-0.35,0.52)	0.06614	(-0.52,0.66)
p-value for 2-way interaction	0.01533		0.03181		0.01507	
Mirtazapine: OEF/OIF	-0.02412	(-0.63,0.58)	0.03701	(-0.85,0.93)	-0.32449	(-0.92,0.27)
Mirtazapine: other era	0.38525	(-0.16,0.93)	-0.52695	(-0.98,-0.07)	-0.33355	(-0.92,0.25)
p-value for 2-way interaction	0.67632		0.50694		0.46492	
Tricyclics: OEF/OIF	0.16814	(-0.7,1.04)	-0.0247	(-1.26,1.21)	-0.80177	(-1.39,-0.22)
Tricyclics: other era	3.69069	(2.93,4.46)	2.18857	(1.55,2.83)	1.68892	(1.08,2.3)
p-value for 2-way interaction	0.07754		0.10755		0.00008	
overall 2-way interaction p-value	0.04885		0.04418		0.00038	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	5840	26089
Mirtazapine	3970	20937
Prazosin	14594	37695
Tricyclics	1715	8922

**Comparison of New Prescription or Dose/Potency Increase of a Cholesterol Medication by Augmenting Medication Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: male	3.7963	(3.19,4.4)	3.01938	(2.44,3.6)	2.81164	(2.11,3.52)
Antipsychotics: female	3.88116	(2.2,5.56)	3.75776	(1.91,5.61)	2.28133	(0.4,4.17)
p-value for 2-way interaction	0.12953		0.15051		0.74903	
Mirtazapine: male	2.5847	(1.93,3.24)	0.79809	(0.19,1.41)	1.00879	(0.31,1.7)
Mirtazapine: female	4.44762	(2.68,6.21)	3.54148	(1.63,5.45)	1.50981	(-0.35,3.37)
p-value for 2-way interaction	0.00434		0.00399		0.41351	
Tricyclics: male	5.76235	(4.82,6.7)	4.1336	(3.24,5.03)	2.49645	(1.79,3.21)
Tricyclics: female	5.04934	(3.19,6.91)	4.56342	(2.53,6.59)	1.97704	(0.1,3.85)
p-value for 2-way interaction	0.24477		0.2255		0.80811	
overall 2-way interaction p-value	0.04066		0.03894		0.8686	

**Number of Windows**

Medications	male	female
Antipsychotics	29413	2516
Mirtazapine	22750	2157
Prazosin	48061	4228
Tricyclics	8777	1860

**Comparison of New Prescription or Dose/Potency Increase of a Cholesterol Medication by Augmenting Medication Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: >=65	1.92265	(0.51,3.33)	-0.3541	(-1.25,0.55)	2.87368	(1.31,4.44)
Antipsychotics: <65	4.29445	(3.67,4.92)	3.40552	(2.75,4.06)	2.7459	(2.01,3.48)
p-value for 2-way interaction	0.00095		0		0.9779	
Mirtazapine: >=65	-0.18022	(-1.53,1.17)	-1.44394	(-2.3,-0.58)	0.19933	(-1.33,1.73)
Mirtazapine: <65	3.40849	(2.72,4.1)	1.57584	(0.87,2.29)	1.24593	(0.52,1.97)
p-value for 2-way interaction	0		0		0.20895	
Tricyclics: >=65	2.34551	(0.15,4.54)	0.77152	(-0.67,2.21)	1.36386	(-0.2,2.93)
Tricyclics: <65	5.36296	(4.44,6.28)	3.69965	(2.75,4.65)	2.68605	(1.95,3.42)
p-value for 2-way interaction	0.0074		0.03024		0.11224	
overall 2-way interaction p-value	0		0		0.2456	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	5253	26676
Mirtazapine	5721	19186
Prazosin	10066	42223
Tricyclics	1634	9003

**Comparison of New Prescription or Dose/Potency Increase of a Cholesterol Medication by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: OEF/OIF	1.54997	(0.56,2.54)	2.20933	(1.01,3.41)	1.33952	(0.2,2.48)
Antipsychotics: other era	2.96143	(2.28,3.64)	2.91873	(2.29,3.54)	2.48938	(1.71,3.27)
p-value for 2-way interaction	0.7335		0.93503		0.82848	
Mirtazapine: OEF/OIF	0.73081	(-0.41,1.87)	0.94745	(-0.42,2.32)	-0.01893	(-1.13,1.09)
Mirtazapine: other era	1.41048	(0.69,2.13)	0.74016	(0.09,1.39)	0.78984	(0.01,1.57)
p-value for 2-way interaction	0.88394		0.6178		0.43492	
Tricyclics: OEF/OIF	1.67338	(0.05,3.3)	1.67534	(-0.25,3.6)	0.30152	(-0.83,1.44)
Tricyclics: other era	3.74891	(2.76,4.74)	3.51064	(2.6,4.42)	2.29583	(1.51,3.08)
p-value for 2-way interaction	0.56057		0.34496		0.10303	
overall 2-way interaction p-value	0.9422		0.71745		0.37608	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	5840	26089
Mirtazapine	3970	20937
Prazosin	14594	37695
Tricyclics	1715	8922

**Comparison of New Prescription or Dose Increase of a Statin by Augmenting Medication Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: male	2.81993	(2.25,3.39)	2.09646	(1.55,2.64)	1.98538	(1.32,2.65)
Antipsychotics: female	3.02259	(1.42,4.63)	2.87919	(1.07,4.68)	1.46427	(-0.34,3.27)
p-value for 2-way interaction	0.20382		0.21987		0.97125	
Mirtazapine: male	1.71762	(1.11,2.33)	0.11307	(-0.46,0.69)	0.28282	(-0.37,0.94)
Mirtazapine: female	3.00659	(1.33,4.69)	2.11541	(0.26,3.97)	0.35898	(-1.4,2.12)
p-value for 2-way interaction	0.04264		0.03813		0.86699	
Tricyclics: male	4.02195	(3.14,4.91)	2.78299	(1.94,3.63)	1.38726	(0.72,2.05)
Tricyclics: female	3.43842	(1.67,5.21)	3.0336	(1.06,5.01)	0.67258	(-1.11,2.45)
p-value for 2-way interaction	0.47696		0.46492		0.73919	
overall 2-way interaction p-value	0.22302		0.21205		0.9643	

**Number of Windows**

Medications	male	female
Antipsychotics	29413	2516
Mirtazapine	22750	2157
Prazosin	48061	4228
Tricyclics	8777	1860

**Comparison of New Prescription or Dose Increase of a Statin by Augmenting Medication Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: >=65	1.32563	(-0.02,2.67)	-0.6047	(-1.46,0.25)	2.11047	(0.61,3.61)
Antipsychotics: <65	3.26037	(2.67,3.85)	2.43487	(1.81,3.05)	1.90587	(1.22,2.6)
p-value for 2-way interaction	0.00312		0		0.97267	
Mirtazapine: >=65	-0.83335	(-2.12,0.46)	-1.70771	(-2.52,-0.89)	-0.62348	(-2.08,0.83)
Mirtazapine: <65	2.41251	(1.76,3.06)	0.76852	(0.1,1.44)	0.49751	(-0.18,1.18)
p-value for 2-way interaction	0		0		0.16435	
Tricyclics: >=65	1.48142	(-0.62,3.58)	0.39656	(-0.97,1.77)	0.74829	(-0.75,2.24)
Tricyclics: <65	3.7293	(2.87,4.59)	2.39976	(1.5,3.3)	1.45228	(0.76,2.14)
p-value for 2-way interaction	0.02773		0.09921		0.33922	
overall 2-way interaction p-value	0.00003		0		0.3811	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	5253	26676
Mirtazapine	5721	19186
Prazosin	10066	42223
Tricyclics	1634	9003

**Comparison of New Prescription or Dose Increase of a Statin by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: OEF/OIF	1.31787	(0.4,2.24)	1.98746	(0.82,3.16)	1.13328	(0.07,2.2)
Antipsychotics: other era	1.97719	(1.33,2.62)	1.93551	(1.34,2.53)	1.58312	(0.84,2.32)
p-value for 2-way interaction	0.6852		0.46746		0.6951	
Mirtazapine: OEF/OIF	0.05273	(-0.99,1.1)	0.09292	(-1.23,1.42)	-0.67793	(-1.69,0.34)
Mirtazapine: other era	0.64664	(-0.03,1.33)	0.05888	(-0.56,0.68)	0.06131	(-0.67,0.79)
p-value for 2-way interaction	0.59589		0.94726		0.20091	
Tricyclics: OEF/OIF	0.94066	(-0.56,2.44)	0.95032	(-0.93,2.83)	-0.29194	(-1.33,0.75)
Tricyclics: other era	2.24996	(1.32,3.18)	2.28276	(1.42,3.15)	1.11913	(0.38,1.86)
p-value for 2-way interaction	0.70935		0.44356		0.11491	
overall 2-way interaction p-value	0.85961		0.70729		0.14978	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	5840	26089
Mirtazapine	3970	20937
Prazosin	14594	37695
Tricyclics	1715	8922

**Comparison of New Prescription or Dose Increase of a Blood Pressure Medication by Augmenting Medication Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: male	3.15766	(2.49,3.83)	1.8847	(1.21,2.56)	1.58246	(0.8,2.36)
Antipsychotics: female	3.73549	(1.74,5.73)	3.01229	(0.77,5.25)	2.39413	(0.2,4.59)
p-value for 2-way interaction	0.21347		0.25031		0.31428	
Mirtazapine: male	3.70143	(2.97,4.43)	0.54176	(-0.18,1.26)	0.5608	(-0.22,1.34)
Mirtazapine: female	4.11507	(2.02,6.21)	2.07017	(-0.25,4.39)	1.58421	(-0.59,3.76)
p-value for 2-way interaction	0.25354		0.19263		0.31642	
Tricyclics: male	6.93015	(5.88,7.99)	3.95248	(2.91,5)	2.6606	(1.87,3.45)
Tricyclics: female	5.89577	(3.67,8.12)	4.40444	(1.94,6.87)	3.82634	(1.6,6.05)
p-value for 2-way interaction	0.65479		0.48336		0.13978	
overall 2-way interaction p-value	0.55261		0.53215		0.51377	

**Number of Windows**

Medications	male	female
Antipsychotics	29413	2516
Mirtazapine	22750	2157
Prazosin	48061	4228
Tricyclics	8777	1860

**Comparison of New Prescription or Dose Increase of a Blood Pressure Medication by Augmenting Medication Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: >=65	2.04275	(0.43,3.66)	-1.21224	(-2.48,0.05)	1.47179	(-0.32,3.26)
Antipsychotics: <65	3.78427	(3.09,4.48)	2.35177	(1.61,3.09)	1.71669	(0.91,2.53)
p-value for 2-way interaction	0.01295		0.00001		0.63955	
Mirtazapine: >=65	1.44352	(-0.13,3.01)	-1.53141	(-2.76,-0.3)	0.26054	(-1.52,2.04)
Mirtazapine: <65	3.87108	(3.1,4.64)	1.10074	(0.29,1.91)	0.74158	(-0.06,1.55)
p-value for 2-way interaction	0.00124		0.00056		0.56681	
Tricyclics: >=65	6.97363	(4.43,9.52)	3.27568	(1.22,5.34)	3.2026	(1.38,5.02)
Tricyclics: <65	5.96101	(4.93,6.99)	3.06784	(1.99,4.15)	2.70827	(1.89,3.52)
p-value for 2-way interaction	0.91337		0.65187		0.90336	
3way interaction p-value	0.00324		0		0.87372	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	5253	26676
Mirtazapine	5721	19186
Prazosin	10066	42223
Tricyclics	1634	9003

**Comparison of New Prescription or Dose Increase of a Blood Pressure Medication by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: OEF/OIF	0.25336	(-0.88,1.39)	0.80662	(-0.68,2.3)	-0.18187	(-1.48,1.11)
Antipsychotics: other era	1.8965	(1.15,2.65)	1.8368	(1.12,2.56)	1.1841	(0.32,2.05)
p-value for 2-way interaction	0.14018		0.34576		0.19822	
Mirtazapine: OEF/OIF	0.19202	(-1.12,1.51)	0.20014	(-1.51,1.91)	-0.60142	(-1.88,0.68)
Mirtazapine: other era	1.92386	(1.12,2.73)	0.4438	(-0.32,1.2)	0.18118	(-0.68,1.04)
p-value for 2-way interaction	0.16238		0.84404		0.31228	
Tricyclics: OEF/OIF	2.17306	(0.29,4.06)	1.76705	(-0.63,4.16)	0.7406	(-0.58,2.06)
Tricyclics: other era	4.04292	(2.94,5.14)	3.25032	(2.2,4.3)	2.268	(1.4,3.14)
p-value for 2-way interaction	0.68642		0.42816		0.34025	
overall 2-way interaction p-value	0.35354		0.73092		0.58203	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	5840	26089
Mirtazapine	3970	20937
Prazosin	14594	37695
Tricyclics	1715	8922